P-selectin inhibitors for treatment of cancer
By reducing P-selectin activity with immunomodulators, the method addresses the immune suppression in brain tumors, enhancing immunotherapy efficacy for brain metastases and glioblastoma treatment.
Patent Information
- Application Number
- CN202380035769.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-16
- Filing Date
- 2023-03-16
- Publication Date
- 2024-12-03
AI Technical Summary
Current treatments for brain metastasized cancers and glioblastoma are ineffective due to the unique brain environment's immune suppression and the lack of understanding of tumor-microglia interactions, with P-selectin mediating microglia-enhanced tumor proliferation and invasion.
Administering a therapeutically effective amount of an agent that specifically reduces P-selectin activity or amount, combined with an immunomodulator, such as immunomodulatory antibodies or small molecule inhibitors, to target P-selectin and enhance immunotherapy efficacy.
The combination therapy sensitizes tumors to immunotherapy, effectively treating brain metastases and primary brain malignancies by reducing P-selectin activity and enhancing immune response.
Smart Images

Figure CN119072333A_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims the benefit of priority to U.S. patent application No. 63 / 320,310 filed on March 16, 2022, the contents of which are incorporated herein by reference in their entirety.
[0003] Field of the Invention and Background Art
[0004] The present invention, in some embodiments thereof, relates to a method of treating brain metastasized cancers and glioblastoma by selectively reducing the activity or amount of P-selectin.
[0005] Primary and secondary brain malignancies affect many patients worldwide, for whom, in most cases, there are no effective treatments. Among primary brain tumors, glioblastoma (GB) is the most lethal and common type, exhibiting high heterogeneity, invasiveness, and irritability. Brain metastases affect 10-20% of all cancer patients, resulting in high mortality. CNS tumors present enormous therapeutic challenges, in part due to the unique environment of the brain exhibiting a highly suppressive environment, low immune infiltration, and the lack of success of current targeted and immunotherapies. Among the brain microenvironment cells, microglia have been shown to promote CNS tumor invasion and immunosuppression. However, the reciprocal mechanisms by which tumor cells alter microglia / macrophage behavior are not fully understood.
[0006] It has been previously demonstrated that P-selectin (SELP) mediates microglia-enhanced GB proliferation and invasion by altering the microglia / macrophage activation state (Yeini et al., Nature Communications 2021, 12(1), 1912).
[0007] Other background technologies include PCT application No. WO2022 / 059008, U.S. Patent Application No. 20200171064 (which teaches the use of isoquercetin or quercetin to treat cancer, including glioblastoma), and U.S. Patent Application No. 20190241665 (which teaches P-selectin inhibitors to treat metastatic cancer).
[0008] Shamay et al., Science Translational Medicine, Vol. 8, No. 345, June 29, 2016, teach that P-selectin is expressed on cancer cells of several human tumor types.
[0009] Ferber et al., eLife 2017;6:e25281. DOI: www.doi.org / 10.7554 / eLife.25281 teaches that P-selectin is expressed not only on tumor endothelial cells but also on glioblastoma cells and can be used as a target for selective delivery of anticancer agents. Summary of the invention
[0010] According to one aspect of the present invention, a method for treating brain metastatic cancer in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of an agent that specifically reduces the amount and / or activity of P-selectin and an immunomodulator, thereby treating the brain metastatic cancer.
[0011] According to one aspect of the present invention, a method for treating pancreatic cancer or renal cancer in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of an agent that specifically reduces the amount and / or activity of P-selectin, thereby treating the pancreatic cancer or renal cancer.
[0012] According to one aspect of the present invention, a method for treating cancer in a subject in need thereof is provided, wherein the cancer is selected from the group consisting of pancreatic cancer, lung cancer, breast cancer, primary melanoma and renal cancer, comprising administering to the subject a therapeutically effective amount of an agent that specifically reduces the amount and / or activity of P-selectin and an immunomodulator, thereby treating the cancer.
[0013] According to an embodiment of the present invention, the brain metastatic cancer is brain metastatic melanoma, brain metastatic breast cancer, brain metastatic lung cancer, or brain metastatic colorectal cancer.
[0014] According to an embodiment of the present invention, the agent that specifically reduces the amount and / or activity of P-selectin specifically binds to P-selectin or a polynucleotide encoding the P-selectin.
[0015] According to an embodiment of the present invention, the agent that specifically reduces the amount and / or activity of P-selectin binds to P-selectin glycoprotein ligand-1 (PSGL-1) or a polynucleotide encoding the PSGL-1.
[0016] According to an embodiment of the present invention, the method further comprises administering an immunomodulator to the subject.
[0017] According to an embodiment of the present invention, the immunomodulator includes an immunomodulatory antibody.
[0018] According to an embodiment of the present invention, the immunomodulatory antibody is selected from the group consisting of anti-CTLA4, anti-CD40, anti-41BB, anti-OX40, anti-PD1, anti-PDL1, anti-LAG3, anti-IDO, and anti-TIGIT.
[0019] According to an embodiment of the present invention, the agent that specifically reduces the amount and / or activity of P-selectin is an inhibitory antibody that binds to and inhibits P-selectin.
[0020] According to an embodiment of the present invention, the inhibitory antibody is Crizanlizumab or Inclacumab.
[0021] According to an embodiment of the present invention, the dosage of Rizanlizumab is about 5 mg / kg once every two weeks or 5 mg / kg once every four weeks.
[0022] According to an embodiment of the present invention, the inhibitory antibody is linked to a therapeutic agent.
[0023] According to an embodiment of the invention, the inhibitory antibody is not linked to a therapeutic agent.
[0024] According to an embodiment of the present invention, the agent that specifically reduces the amount and / or activity of P-selectin is a small molecule agent.
[0025] According to an embodiment of the present invention, the agent that specifically reduces the amount and / or activity of P-selectin is a polynucleotide agent.
[0026] According to an embodiment of the present invention, the agent that specifically reduces the amount and / or activity of P-selectin is co-formulated with the immunomodulator.
[0027] According to an embodiment of the present invention, the agent that specifically reduces the amount and / or activity of P-selectin is contained in a nanoparticle.
[0028] According to an embodiment of the present invention, the nanoparticle is linked to a targeting moiety to enhance transport across the blood-brain barrier.
[0029] According to an embodiment of the present invention, the agent that specifically reduces the amount and / or activity of P-selectin is linked to a targeting moiety to enhance delivery across the blood-brain barrier.
[0030] According to one aspect of the present invention, a method for treating glioblastoma or brain metastatic melanoma in a subject in need thereof is provided, comprising administering a therapeutically effective amount of rizumab and an anti-PD1 antibody to the subject, thereby treating the glioblastoma or brain metastatic melanoma.
[0031] According to an embodiment of the present invention, the rizumab is administered once every two weeks or every four weeks at a dose of about 5 mg / kg.
[0032] According to an embodiment of the present invention, the anti-PD1 antibody is selected from the group consisting of Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo) and Dostalimab (Jemperli).
[0033] According to an embodiment of the present invention, the anti-PD1 antibody is nivolumab.
[0034] According to an embodiment of the present invention, the rizumab and the anti-PD1 antibody are initially administered once every two weeks for at least four weeks.
[0035] According to an embodiment of the present invention, the dosage of the anti-PD1 antibody is about 3 mg / kg once every two weeks.
[0036] Unless otherwise defined, all technical and / or scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the invention belongs. Although methods and materials similar or equivalent to the methods and materials described herein may be used in implementing or testing embodiments of the present invention, exemplary methods and / or materials are described below. In the event of a conflict, the patent specification, including definitions, shall prevail. In addition, materials, methods, and examples are illustrative only and are not intended to be limiting. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Some embodiments of the present invention are described herein by way of example only and with reference to the accompanying drawings. A detailed description will now be given with specific reference to the accompanying drawings, with emphasis being placed on the fact that the details shown are provided only as examples for purposes of illustrative discussion of embodiments of the present invention. In this regard, the description in conjunction with the accompanying drawings will provide a person skilled in the art with a clear understanding of how to implement embodiments of the present invention.
[0038] In the attached picture:
[0039] Figures 1A to 1C: PD-1 / PD-L1 is highly expressed in tissues of glioblastoma patients, and its expression is correlated with SELP / PSGL-1 expression. Analysis of the glioblastoma database showed that PD-1 (PDCD1) and PD-L1 (CD207) were highly expressed in GB samples compared with healthy human brain tissue and low-grade gliomas (AB), and there was a positive correlation between PSGL-1 (SELPLG) expression and PD-1 and PD-L1 expression, and between SELP expression and PD-1 expression. The analysis was performed using the GlioVis data portal.
[0040] FIG. 2A to FIG. 2B : SELP, PSGL-1, PD-1, and PD-L1 are co-expressed in multiple patient BM and DIPG samples. A. Immunostaining showed that SELP was highly expressed in melanoma, breast, lung, and CRC BM, and DIPG patient samples. PSGL-1 was found to be highly expressed in melanoma, breast, and lung BM, and DIPG patient samples. B. Immunostaining showed that PD-1 was highly expressed in melanoma and lung BM, and PD-L1 was highly expressed in melanoma, breast, lung, and CRC BM, and in DIPG patient samples. All samples were compared to normal human brain tissue, which showed lower expression of all stained markers.
[0041] FIG. 3A to FIG. 3B :SELP, PSGL-1, PD-1, and PD-L1 are co-expressed in various patient primary tumor samples. A. Immunostaining shows that SELP and PSGL-1 are highly expressed in primary melanoma, breast cancer, and lung cancer patient samples, and SELP is highly expressed in primary PDAC patient samples. B. Immunostaining shows that PD-1 and PD-L1 are highly expressed in primary melanoma, PDAC, and lung cancer patient samples.
[0042] FIG. 4A to FIG. 4C : Microglia are activated in melanoma brain metastases in vivo and promote melanoma cell proliferation and invasion in vitro. A. Iba-1 immunostaining shows positive staining of activated microglia at the tumor site using a patient-derived MBM mouse model and patient FFPE samples. B. Co-culture proliferation assay shows increased proliferation of mouse RET melanoma cells after addition of primary mouse microglia in a concentration-dependent manner. C. 3D spheroid invasion assay shows increased growth and invasion of mouse D4M melanoma cells when BV2 mouse microglia are incorporated into spheroids.
[0043] FIG. 5A to FIG. 5C: SELP is highly expressed in 2D cultures and 3D spheroids of melanoma cells. A. Flow cytometric analysis shows that SELP is highly expressed in 2D cultured human A375 and mouse B16-F10 and Ret melanoma cell lines. B to C. Flow cytometric analysis shows that SELP is overexpressed in WM115 (B) and D4M.3A (C) 3D tumor spheroids compared to 2D cultures.
[0044] FIG. 6A to FIG. 6B Figure : Combination therapy of SELP inhibitors and anti-PD-1 induces anticancer activity of splenocytes against D4M.3A melanoma spheroids in the presence of microglia. A to B. D4M.3A spheroids composed of cancer cells alone (A) or cancer cells and primary mouse microglia (B) were cocultured with freshly isolated mouse splenocytes. Spheroids were either untreated or treated with anti-PD-1 antibody, SELP inhibitor (SELPi), or the combination. Combination therapy of SELPi and anti-PD-1 showed the highest inhibition of spheroid growth compared with SELPi or anti-PD-1 monotherapy.
[0045] Figures 7A to 7B :SELP axis mediates breast cancer spheroid invasion. A. Flow cytometric analysis shows that SELP is highly expressed in mouse BRCA-mutated EMT6 breast cancer 3D spheroids. B. Human MDA-BM-231 3D spheroids have enhanced invasion ability when co-cultured with brain microenvironment cells, while the invasion ability is reduced after treatment with SELP inhibitor (SELPi).
[0046] FIG. 8A to FIG. 8D :SELP plays a role in lung cancer-microglia interactions and mediates lung cancer spheroid growth. A. Growth of human A549 spheroids was increased in the presence of human microglia compared to spheroids composed of A549 cells alone. B. Flow cytometric analysis showed that A549 cells expressed high levels of SELP, while human microglia expressed high levels of PSGL-1 when co-cultured in 3D spheroids. C. Treatment with a SELP inhibitor (SELPi) inhibited A549 spheroid growth in the presence of human microglia. D. SELP treatment reduced the growth and invasion of A549 spheroids in Matrigel in a dose-dependent manner. DETAILED DESCRIPTION
[0047] In some embodiments of the present invention, there is provided a method for treating brain metastasis and glioblastoma by selectively reducing the activity or amount of P-selectin.
[0048] Before explaining at least one embodiment of the present invention in detail, it should be understood that the application of the present invention is not necessarily limited to the details set forth in the following description or the details illustrated by the examples. The present invention is capable of other embodiments or of being implemented or realized in various ways.
[0049] SELP was recently found to be overexpressed in melanoma brain metastasis (MBM) cells and tissues in both patient-derived samples and mouse models. 40% to 50% of patients with stage IV melanoma will develop brain metastases. Combinations of anti-CTLA-4 antibodies (ipilimumab) and anti-PD-1 antibodies (pembrolizumab, nivolumab, cemiplimab) have been shown to be effective in patients with melanoma brain metastases, with response rates as high as 50% in asymptomatic patients. However, heterogeneity of immune responses and resistance to therapy are often observed due to the infiltration of different adaptive and innate immune cells into the tumor.
[0050] The present inventors have now demonstrated that combining anti-PD1 (or anti-PD-L1, such as Tecentriq (atezolizumab), Bavencio (avelumab) and Imfinzi (durvalumab), or small molecule inhibitors of PD-L1) with anti-SELP (antibody or small molecule) can sensitize tumors to immunotherapy ( FIG. 6 ). Therefore, the present inventors propose that SELP inhibition combined with immunotherapy such as checkpoint modulators, vaccines or CAR T therapy has therapeutic potential for patients with primary and secondary brain malignancies, as well as primary tumors expressing SELP (e.g., PDAC / pancreas, RCC / kidney, melanoma / skin and lung) (see FIG. 2A to FIG. 2B and FIG. 3A to FIG. 3B ).
[0051] Therefore, according to one aspect of the present invention, a method for treating brain metastasis in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of an agent that specifically reduces the amount and / or activity of P-selectin and an immunomodulator, thereby treating brain metastasis.
[0052] According to another aspect of the present invention, a method for treating pancreatic cancer or renal cancer in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of an agent that specifically reduces the amount and / or activity of P-selectin, thereby treating pancreatic cancer or renal cancer.
[0053] According to another aspect of the present invention, a method for treating cancer in a subject in need thereof is provided, wherein the cancer is selected from the group consisting of pancreatic cancer, lung cancer, breast cancer, primary melanoma and renal cancer, comprising administering to the subject a therapeutically effective amount of an agent that specifically reduces the amount and / or activity of P-selectin and an immunomodulator, thereby treating the cancer.
[0054] As used herein, the term "subject" refers to a mammal, such as a rodent, a feline, a canine, and a primate. Preferably, the subject according to the present invention is a human. In one embodiment, the subject is a non-surgical and non-radiated subject. In one embodiment, the subject has a tumor comprising two or more lobes.
[0055] P-selectin is a member of the selectin family of adhesion glycoproteins, which includes L-selectin and E-selectin. Selectins mediate recruitment, initial tethering and rolling, and adhesion of leukocytes at sites of inflammation. P-selectin is stored in Weibel-Palade bodies of endothelial cells and in α-granules of platelets, and rapidly moves to the plasma membrane upon stimulation by vasoactive substances such as histamine and thrombin.
[0056] P-selectin is a transmembrane glycoprotein (SwissProt sequence P16109) consisting of an NH2-terminal lectin domain followed by an epidermal growth factor (EGF)-like domain and nine consensus repeat domains. It is anchored in the membrane via a single transmembrane domain and contains a small cytoplasmic tail.
[0057] The Uniprot accession number of human P-selectin (also known as SELP) is P16109, and the REFSEQ mRNA accession number is NM_003005.4.
[0058] P-selectin plays a central role in recruiting leukocytes to sites of inflammation and thrombosis by binding to its counter-receptor, P-selectin glycoprotein ligand-1 (PSGL-1) (or PSGL-1-like receptor on sickle cells), which is a mucin-like glycoprotein that is intrinsically expressed on leukocytes including neutrophils, monocytes, platelets, and some endothelial cells.
[0059] The Uniprot accession number of human PSGL-1 is Q14242, and the REFSEQ mRNA accession number is NM_001206609.2 or NM_003006.4.
[0060] Thus, the present invention contemplates downregulating the function of P-selectin by using (1) P-selectin antibodies, (2) PSGL-1 antibodies, (3) small molecules that mimic the PSGL-1 binding domain, and (4) other molecules that disrupt the binding of P-selectin to PSGL-1. Such agents are further described below.
[0061] In another embodiment, the agent downregulates the amount of P-selectin by decreasing the expression of P-selectin.
[0062] In another embodiment, the agent downregulates the expression of PSGL-1.
[0063] The phrase "downregulate expression" as used herein refers to the use of various molecules that interfere with transcription and / or translation (e.g., RNA silencing agents, CRISPR / Cas-9) or at the protein level (e.g., aptamers, small molecules and inhibitory peptides, antagonists, enzymes that cleave polypeptides, antibodies, etc.) to downregulate the expression of P-selectin or PSGL-1 at the genomic (e.g., homologous recombination and site-specific endonucleases) and / or transcriptional levels.
[0064] For the same culture conditions, the expression is typically compared to expression in cells of the same species not contacted with the agent or contacted with a vehicle control (also referred to as a control).
[0065] Downregulation of expression may be temporary or permanent.
[0066] According to a specific embodiment, down-regulated expression refers to the detection of the absence of mRNA and / or protein by RT-PCR or Western blot, respectively.
[0067] According to other specific embodiments, down-regulating expression refers to detecting the reduction of the level of mRNA and / or protein by RT-PCR or Western blot, respectively. The reduction can be at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or at least 99% reduction.
[0068] Non-limiting examples of agents capable of downregulating the expression of P-selectin or PSGL-1 are described in detail below.
[0069] Downregulation of nucleic acid levels:
[0070] Downregulation of nucleic acid levels is generally achieved using a nucleic acid agent having a nucleic acid backbone, DNA, RNA, mimetics thereof, or a combination thereof. The nucleic acid agent can be encoded from a DNA molecule or provided to the cell itself.
[0071] According to one embodiment, the down-regulator is a polynucleotide.
[0072] According to one embodiment, the down-regulator is a polynucleotide capable of hybridizing with the gene or mRNA encoding P-selectin.
[0073] According to a specific embodiment, the down-regulator is a polynucleotide capable of hybridizing with a gene or mRNA encoding PSGL-1.
[0074] According to one embodiment, the down-regulator directly interacts with P-selectin.
[0075] According to one embodiment, the agent binds directly to P-selectin.
[0076] According to one embodiment, the agent binds P-selectin indirectly (eg, binds an effector of P-selectin).
[0077] According to a specific embodiment, the down-regulator is an RNA silencing agent or a genome editing agent.
[0078] Therefore, downregulation of P-selectin or PSGL-1 can be achieved by RNA silencing.
[0079] As used herein, the phrase "RNA silencing" refers to a group of regulatory mechanisms mediated by RNA molecules [e.g., RNA interference (RNAi), transcriptional gene silencing (TGS), post-transcriptional gene silencing (PTGS), suppression, co-suppression and translational suppression], which result in the inhibition or "silencing" of the expression of the corresponding protein-coding gene. RNA silencing has been observed in many types of organisms, including plants, animals and fungi.
[0080] As used herein, the term "RNA silencing agent" refers to an RNA that can specifically inhibit or "silence" the expression of a target gene. In certain embodiments, RNA silencing agents can prevent the complete processing (e.g., complete translation and / or expression) of mRNA molecules by a post-transcriptional silencing mechanism. RNA silencing agents include non-coding RNA molecules, such as RNA double strands comprising paired chains, and precursor RNAs that can produce such small non-coding RNAs. Exemplary RNA silencing agents include dsRNA, such as siRNA, miRNA, and shRNA. RNA silencing agents can be administered as naked oligonucleotides, can contain modified bases, can be a stable oligonucleotide, embedded or bound to a nanoparticle or any nanocarrier (polymer, lipid-LNP, liposome, micelle, etc.) - see, for example, Scampalin et al., Biotechnology Advances, Vol. 33, No. 6, Part 3, November 1, 2015, pp. 1294-1309.
[0081] In one embodiment, the RNA silencing agent is capable of inducing RNA interference.
[0082] In another embodiment, the RNA silencing agent is capable of mediating translational repression.
[0083] According to one embodiment of the present invention, the RNA silencing agent is specific for the target RNA (e.g., P-selectin) and does not cross-inhibit or silence other targets or splice variants that exhibit 99% or less overall homology to the target gene as detected by PCR, Western blotting, immunohistochemistry and / or flow cytometry, for example, less than 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% overall homology to the target gene.
[0084] RNA interference refers to the process of sequence-specific post-transcriptional gene silencing in animals mediated by short interfering RNA (siRNA).
[0085] The following is a detailed description of RNA silencing agents that can be used according to specific embodiments of the present invention.
[0086] DsRNA, siRNA, and shRNA - The presence of long dsRNA in cells stimulates the activity of a ribonuclease III enzyme called Dicer. Dicer is involved in processing dsRNA into short fragments of dsRNA, called short interfering RNA (siRNA). Short interfering RNAs resulting from Dicer activity are typically about 21 to 23 nucleotides in length and contain about 19 base pair duplexes. The RNAi reaction also has an endonuclease complex, often referred to as an RNA-induced silencing complex (RISC), which mediates the cleavage of single-stranded RNAs having a sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the target RNA occurs in the middle of the region complementary to the antisense strand of the siRNA duplex.
[0087] Thus, some embodiments of the invention contemplate the use of dsRNA to downregulate protein expression of mRNA.
[0088] According to one embodiment, a dsRNA with a length of more than 30 bp is used. Various studies have confirmed that long dsRNA can be used to silence gene expression without inducing stress response or causing significant off-target effects - see, for example [Strau et al., Nucleic Acids Research, 2006, Vol. 34, No. 13, 3803-3810; Bhargava A et al., Brain Res. Protoc. 2004; 13: 115-125; Diallo M. et al., Oligonucleos. 2003; 13: 381-392; Paddison PJ et al., Proc. Natl Acad. Sci. USA. 2002; 99: 1443-1448; Chen N. et al., FEBS Lett. 2004; 573: 127-134].
[0089] According to some embodiments of the invention, dsRNA is provided in cells in which the interferon pathway is not activated, see, for example, Bealey et al., PNAS, 2001, Vol. 98, pp. 14428-14433 and Diallo et al., Oligonucleosides, Oct. 1, 2003, 13(5): 381-392. doi: 10.1089 / 154545703322617069.
[0090] According to one embodiment of the present invention, long dsRNA is specifically designed not to induce interferon and PKR pathways to downregulate gene expression. For example, Shinagawa and Ishii [Genes & Dev. 17 (11): 1340-1345, 2003] have developed a vector named pDECAP for expressing long double-stranded RNA from an RNA polymerase II (Pol II) promoter. Since transcripts from pDECAP lack a 5'-cap structure and a 3'-poly (A) tail, which promotes the export of ds-RNA to the cytoplasm, long ds-RNA from pDECAP does not induce an interferon response.
[0091] Another approach to circumvent the interferon and PKR pathways in mammalian systems is to introduce small inhibitory RNA (siRNA) by transfection or endogenous expression.
[0092] The term "siRNA" refers to a small interfering RNA duplex (usually between 18 and 30 base pairs) that induces the RNA interference (RNA interference, RNAi) pathway. Typically, siRNA is chemically synthesized in the form of 21mer, with a central 19bp duplex region and 2 base 3' overhangs symmetrical at the ends, although it has recently been reported that the effectiveness of chemically synthesized RNA duplexes of 25 to 30 bases in length can be increased by up to 100 times compared to 21mers at the same position. The increased effectiveness observed using longer RNA to trigger RNAi indicates that it is due to providing a substrate (27mer) to the Dicer enzyme, rather than a product (21mer), which increases the rate or efficiency of the siRNA duplex entering RISC.
[0093] It has been found that the position of the 3'-overhang affects the potency of siRNA, and asymmetric duplexes with 3'-overhangs on the antisense strand are generally more effective than asymmetric duplexes with 3'-overhangs on the sense strand (Ross et al., 2005). This can be attributed to asymmetric strand loading in RISC, as the opposite pattern of efficacy was observed when targeting antisense transcripts.
[0094] The strands of double-stranded interfering RNA (eg, siRNA) can be linked to form a hairpin or stem-loop structure (eg, shRNA). Therefore, as described above, the RNA silencing agent of some embodiments of the present invention can also be a short hairpin RNA (shRNA).
[0095] miRNA and miRNA Mimics - According to another embodiment, the RNA silencing agent can be a miRNA.
[0096] The terms "microRNA," "miRNA," and "miR" are synonymous and refer to a group of noncoding single-stranded RNA molecules of approximately 19 to 28 nucleotides in length that regulate gene expression. miRNAs are present in a variety of organisms and have been shown to play a role in development, homeostasis, and disease etiology.
[0097] Antisense - Antisense is a single-stranded RNA designed to prevent or inhibit the expression of a gene by specifically hybridizing to the mRNA of the gene. Downregulation of P-selectin can be achieved using antisense polynucleotides that are able to specifically hybridize to mRNA transcripts encoding P-selectin. Downregulation of PSGL-1 can be achieved using antisense polynucleotides that are able to specifically hybridize to mRNA transcripts encoding PSGL-1.
[0098] In designing antisense molecules that can be used to effectively downregulate P-selectin or PSGL-1, two aspects important to the antisense approach must be considered. The first is the delivery of the oligonucleotide into the cytoplasm of the appropriate cell, while the second is the design of an oligonucleotide that specifically binds to the selected mRNA within the cell in a manner that inhibits its translation.
[0099] Down-regulation can be achieved by inactivating a gene (ie, P-selectin or PSGL-1 gene) by introducing targeted mutations involving loss-of-function changes (eg, point mutations, deletions, and insertions) in the gene structure.
[0100] As used herein, the phrase "loss-of-function alteration" refers to any mutation in the DNA sequence of a gene that results in downregulation of the expression level and / or activity of the expressed product, ie, mRNA transcript and / or translated protein. Non-limiting examples of such loss-of-function changes include missense mutations, i.e., mutations that change an amino acid residue in a protein to another amino acid residue and thereby eliminate the enzymatic activity of the protein; nonsense mutations, i.e., mutations that introduce a stop codon, e.g., an early stop codon, into a protein, which results in a shorter protein and lacking enzymatic activity; frame-shift mutations, i.e., mutations that are usually deletions or insertions of nucleic acids that alter the reading frame of a protein and can result in premature termination (e.g., a truncated protein lacking enzymatic activity) by introducing a stop codon in a reading frame, or introducing a stop codon into a longer amino acid sequence (e.g., a readthrough protein), which affects the secondary or tertiary structure of the protein and results in a non-functional protein lacking the enzymatic activity of the non-mutated polypeptide; readthrough mutations caused by frame-shift mutations or modified stop codon mutations (i.e., when the stop codon is mutated to an amino acid codon) a promoter mutation, i.e., a mutation in a promoter sequence, usually located 5' to the transcription start site of a gene, which results in downregulation of a particular gene product; a regulatory mutation, i.e., a mutation in the upstream or downstream region of a gene or within a gene, which affects the expression of a gene product; a deletion mutation, i.e., a mutation that deletes a coding nucleic acid in a gene sequence, which may result in a frameshift mutation or an in-frame mutation (within the coding sequence, the deletion of one or more amino acid codons); an insertion mutation, i.e., a mutation that inserts a coding or non-coding nucleic acid into a gene sequence, which may result in a frameshift mutation or an in-frame insertion of one or more amino acid codons; an inversion, i.e., a mutation that results in an inverted coding or non-coding sequence; a splicing mutation, i.e., a mutation that results in a splicing abnormality or poor splicing; and a duplication mutation, i.e., a mutation that results in a duplication of a coding or non-coding sequence, which may be in-frame or may result in a frameshift.
[0101] According to one embodiment, a loss-of-function alteration of a gene may include at least one allele of the gene.
[0102] The term "allele" as used herein refers to any of one or more alternative forms of a gene locus, all of which are associated with a trait or characteristic. In a diploid cell or organism, the two alleles of a given gene occupy corresponding sites on a pair of homologous chromosomes.
[0103] According to other embodiments, the loss-of-function alteration of a gene comprises two alleles of the gene. In this case, P-selectin or PSGL-1 may be in a homozygous form or a heterozygous form.
[0104] Methods for introducing nucleic acid changes into a gene of interest are well known in the art [see, e.g., Monk D., Genesis (2013) 51:-618; Capecchi, Science (1989) 244:1288-1292; Santiago et al., Proc Natl Acad Sci USA (2008) 105:5809-5814; International Patent Application Nos. WO 2014085593, WO 2009071334 and WO 2014085594]. 2011146121; U.S. Patent Nos. 8771945, 8586526, 6774279 and UP Patent Application Publication Nos. 20030232410, 20050026157, US20060014264; the contents of which are incorporated by reference in their entirety], and include targeted homologous recombination, site-specific recombinases, PB transposases, and genome editing by engineered nucleases. Reagents for introducing nucleic acid changes into a gene of interest can be designed from publicly available sources or purchased from Transposagen, Addgene, and Sangamo Biosciences.
[0105] Following is a description of various exemplary methods for introducing nucleic acid alterations into a gene of interest, as well as reagents for practicing the same that can be used according to specific embodiments of the invention.
[0106] Genome editing using engineered endonucleases - This approach refers to a reverse genetics approach that uses artificially engineered nucleases to cut and create specific double-strand breaks at desired locations in the genome, which are then repaired by endogenous processes in the cell, such as homology directed repair (HDR) and non-homologous end-joining (NHEJ). NHEJ directly joins the DNA ends of the double-strand break, while HDR uses homologous sequences as templates to regenerate the missing DNA sequence at the break point. In order to introduce specific nucleotide modifications into genomic DNA, a template containing the desired sequence must be present during HDR. Traditional restriction endonucleases cannot be used for genome editing because most restriction endonucleases recognize several base pairs on DNA as targets, and the recognized base pair combinations are very likely to appear at many locations in the genome, resulting in multiple cuts that are not limited to the desired location. To overcome this challenge and establish site-specific single-strand or double-strand breaks, several different types of nucleases have been discovered and bioengineered to date. These include meganucleases, zinc finger nucleases (ZFNs), transcription-activator like effector nucleases (TALENs), and CRISPR / Cas systems.
[0107] Meganucleases - Meganucleases are generally divided into four families: LAGLIDADG family, GIY-YIG family, His-Cysbox family and HNH family. These families are characterized by structural motifs that affect catalytic activity and recognition sequences. For example, members of the LAGLIDADG family are characterized by having one or two conserved copies of the LAGLIDADG motif. The four meganuclease families differ greatly from each other in terms of conserved structural elements, DNA recognition sequence specificity and catalytic activity. Meganucleases are common in microbial species and have the unique property of very long recognition sequences (>14bp), thus giving them natural specificity when cutting a desired position. It can be used to make site-specific double-strand breaks in genome editing. Those skilled in the art can use these naturally occurring meganucleases, however, the number of such naturally occurring meganucleases is limited. In order to overcome this challenge, mutagenesis and high-throughput screening methods have been used to establish meganucleases variants that recognize unique sequences. For example, various meganucleases have been fused to establish hybrid enzymes that recognize a new sequence. Alternatively, the DNA-interacting amino acids of the meganuclease can be altered to design sequence-specific meganucleases (see, e.g., U.S. Pat. No. 8,021,867). The meganucleases can be designed using methods such as those described in Cherteau, MT et al., Nature Methods (2012) 9:073-975; U.S. Pat. Nos. 8,304,222; 8,021,867; 8,119,381; 8,124,369; 8,129,134; 8,133,697; 8,143,015; 8,143,016; 8,148,098; or 8,163,514, the contents of which are incorporated herein by reference in their entirety. Alternatively, commercially available technologies such as Precision Biosciences' Directed Nuclease Editor can be used. TM Genome editing techniques to obtain meganucleases with site-specific cleavage properties.
[0108] ZFNs and TALENs - Two different types of engineered nucleases, zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), have been shown to be effective in generating targeted double-strand breaks (Christin et al., 2010; Kim et al., 1996; Lee et al., 2011; Mahfouz et al., 2011; Miller et al., 2010).
[0109] Basically, ZFN and TALEN restriction endonuclease technologies utilize a non-specific DNA-cutting enzyme that is linked to a specific DNA binding domain (a series of zinc finger domains or TALE repeats, respectively). Typically, restriction enzymes are selected in which the DNA recognition site and the cleavage site are separated from each other. The cleavage portion is separated and then connected to a DNA binding domain, resulting in an endonuclease with extremely high specificity for a desired sequence. A typical restriction enzyme with this property is Fokl. In addition, Fokl has the advantage of requiring dimerization to have nuclease activity, which means that specificity is significantly increased because each nuclease partner recognizes a unique DNA sequence. To enhance this effect, Fokl nucleases have been designed to function only as heterodimers and have higher catalytic activity. Heterodimer functional nucleases avoid the possibility of unnecessary homodimer activity, thereby increasing the specificity of double-strand breaks.
[0110] Thus, for example, to target a specific site, ZFNs and TALENs are constructed as nuclease pairs, each member of which is designed to bind to adjacent sequences at the target site. After transient expression in cells, the nucleases bind to their target sites, and the FokI domains heterodimerize to produce double-strand breaks. Repair of these double-strand breaks by the non-homologous end-joining (NHEJ) pathway typically results in small deletions or small sequence insertions. Since each repair performed by NHEJ is unique, a range of allelic sequences with different deletions can be generated at the target site using a single nuclease pair. The length of the deletions typically ranges from a few base pairs to hundreds of base pairs, but larger deletions have been successfully generated in cell culture by using two pairs of nucleases simultaneously (Carlson et al., 2012; Li et al., 2010). Furthermore, when DNA fragments with homology to the target region are introduced together with a nuclease pair, double-strand breaks can be repaired by homology-directed repair to produce specific modifications ( Lee et al., 2011 ; Miller et al., 2010 ; Urnov et al., 2005 ).
[0111] Although the nuclease portion of ZFNs and TALENs has similar properties, the difference between these engineered nucleases lies in their DNA recognition peptides. ZFNs rely on Cys2-His2 zinc fingers, and TALENs rely on TALEs. Both of these DNA recognition peptide domains have the characteristic of being naturally present in their protein combinations. Cys2-His2 zinc fingers are usually found in repeating sequences separated by 3 bp and are found in various nucleic acid-interacting proteins in various combinations. On the other hand, TALEs appear in a repeating form, with a one-to-one recognition ratio between amino acids and recognized nucleotide pairs. Since both zinc fingers and TALEs appear in a repeating pattern, different combinations can be tried to establish various sequence specificities. Methods for making site-specific zinc finger nucleases include, for example, modular assembly (in which zinc fingers associated with triplet sequences are connected in a row to cover the desired sequence), OPEN (in bacterial systems, low stringency selection of peptide domains for triplet nucleotides, followed by high stringency selection of peptide combinations for the final target), and bacterial single-hybrid screening of zinc finger libraries. ZFNs can also be obtained from Sangamo Biosciences. TM (Richmond, CA) for design and commercial acquisition.
[0112] Methods for designing and obtaining TALENs have been described in the following literature: Ryan et al., Nature Biotechnology, May 2012;30(5):460-5; Miller et al., Nat Biotechnol. (2011)29:143-148; Chermak et al., Nucleic Acids Research (2011)39(12):e82 and Zhang et al., Nature Biotechnology (2011)29(2):149-53. The Mayo Clinic recently launched a recently developed web-based program, Mojo Hand, to design TAL and TALEN constructs for genome editing applications (accessible via www.talendesign.org). TALENs are also available from Sangamo Biosciences. TM (Richmond, CA) for design and commercial acquisition.
[0113] CRISPR-Cas system - Many bacteria and archaea contain endogenous RNA-based adaptive immune systems that can degrade nucleic acids of invading phages and plasmids. These systems are composed of clustered regularly interspaced short palindromic repeat (CRISPR) genes that produce RNA components and CRISPR associated (Cas) genes that encode protein components. CRISPR RNA (crRNA) contains short segments homologous to specific viruses and plasmids and serves as a guide to direct the Cas nuclease to degrade complementary nucleic acids of the corresponding pathogen. Studies on the type II CRISPR / Cas system of Streptococcus pyogenes have shown that three components form an RNA / protein complex and together are sufficient to achieve sequence-specific nuclease activity: Cas9 nuclease, crRNA containing 20 base pairs homologous to the target sequence, and trans-activating crRNA (tracrRNA) (Ginek et al., Science (2012) 337: 816-821). It was further demonstrated that a synthetic chimeric guide RNA (gRNA) fused from crRNA and tracrRNA can direct Cas9 in vitro to cleave a DNA target complementary to the crRNA. It was also demonstrated that transient expression of Cas9 combined with a synthetic gRNA can be used to generate targeted double-stranded brakes in a variety of different species (Zhao et al., 2013; Cong et al., 2013; DiCarlo et al., 2013; Huang et al., 2013a, b; Ginek et al., 2013; Mali et al., 2013).
[0114] The CRIPSR / Cas system for genome editing consists of two distinct components: guide RNA and an endonuclease, such as Cas9.
[0115] The gRNA is typically a 20-nucleotide sequence that encodes a combination of a target homologous sequence (crRNA) and an endogenous bacterial RNA that connects the crRNA to the Cas9 nuclease (tracrRNA) in a single chimeric transcript. The gRNA / Cas9 complex is recruited to the target sequence by base pairing between the gRNA sequence and the complementary genomic DNA. In order to successfully bind Cas9, the genomic target sequence must also contain the correct protospacer adjacent motif (PAM) sequence immediately following the target sequence. The binding of the gRNA / Cas9 complex locates Cas9 to the genomic target sequence, allowing Cas9 to cut both strands of DNA, resulting in double-strand breaks. Just like ZFN and TALEN, double-strand breaks generated by CRISPR / Cas can undergo homologous recombination or NHEJ.
[0116] The Cas9 nuclease has two functional domains: RuvC and HNH, each of which cuts a different DNA strand. When both domains are active, Cas9 causes double-strand breaks in genomic DNA.
[0117] A significant advantage of CRISPR / Cas is the high efficiency of this system combined with the ability to easily create synthetic gRNAs, allowing for simultaneous targeting of multiple genes. In addition, most cells carrying mutations have biallelic mutations in the target genes.
[0118] However, the apparent flexibility in the base-pairing interactions between the gRNA sequence and the genomic DNA target sequence allows for imperfect matches to the target sequence for cleavage by Cas9.
[0119] Improved versions of the Cas9 enzyme containing a single inactive catalytic domain (RuvC or HNH) are called "nickases". With only one active nuclease domain, the Cas9 nickase can only cut one strand of the target DNA, resulting in a single-strand break or "nick". Single-strand breaks or nicks are usually repaired quickly through the HDR pathway, using an intact complementary DNA strand as a template. However, the two proximal, opposite-strand nicks introduced by the Cas9 nickase are considered double-strand breaks, which are often referred to as "double-nick" CRISPR systems. Double nicks can be repaired by NHEJ or HDR, depending on the desired effect on the gene target. Therefore, if specificity and reduced off-target effects are critical, a Cas9 nickase is used to create double nicks by designing two gRNAs in which the target sequences are in close proximity on opposite strands of the genomic DNA, which will reduce off-target effects because using either gRNA alone will result in a nick that does not alter the genomic DNA.
[0120] A modified version of the Cas9 enzyme containing two inactive catalytic domains (dead Cas9 or dCas9) has no nuclease activity but is still able to bind to DNA based on gRNA specificity. dCas9 can be used as a platform for DNA transcription regulators by fusing the inactive enzyme to known regulatory domains to activate or repress gene expression. For example, dCas9 alone binding to a target sequence in genomic DNA interferes with gene transcription.
[0121] There are many publicly available tools that can be used to help select and / or design target sequences, as well as lists of unique gRNAs determined by bioinformatics for different genes in different species, such as TargetFinder from Feng Zhang's laboratory, Target Finder from Michael Boutros' laboratory (E-CRISP), RGEN Tools: Cas-OFFinder, CasFinder: A Flexible Algorithm for Identifying Specific Cas9 Targets in the Genome, and CRISPR Optimal Target Finder.
[0122] Non-limiting examples of gRNA sequences that can be used in some embodiments of the invention are described in the literature (Sanjana NE, Shalem O., Zhang F. Nat Methods. 2014 Aug; 11(8):783-4) and on the genscript website, see www.genscript.com / gRNA-detail / 6403 / SELP-CRISPR-guide-RNA.
[0123] According to a specific embodiment, the gRNA sequence does not have significant off-target effects. Methods for determining off-target effects are well known in the art, such as BGI Human Whole Genome Sequencing (described in Nature; 491: 65-56.2012), next generation sequencing (NGS), for example, using commercially available kits such as Alt-R-Genom Editing (IDT detection kit) or Sure select target enrichment <1% variant allele frequency (Agilent Technologies).
[0124] In order to use the CRISPR system, both gRNA and Cas9 should be expressed in a target cell. The insertion vector may contain two boxes on a single plasmid, or the two boxes may be expressed by two separate plasmids. CRISPR plasmids are commercially available, for example, px330 plasmids from Addgene. Alternatively, gRNA and Cas9 may be transfected into target cells simultaneously without plasmids using, for example, a transfection reagent such as CRISPRMAX [see, for example, Yu et al. (2016) JD1 Biotechnol Lett. 38 (6): 919-29]. In some cells, electroporation may improve transfection of gRNA and Cas9 [see, for example, Liang et al. (2015) Journal of Biotechnology 208, 2015, pp. 44-53; and Liang et al. (2017) Journal of Biotechnology, Vol. 241, 2017, pp. 136-146].
[0125] "Hit and run" or "in-out" - involves a two-step recombination procedure. In the first step, an insertion vector containing a dual positive / negative selection marker cassette is used to introduce the desired sequence changes. The insertion vector contains a single continuous region homologous to the target locus and is modified to carry the mutation of interest. This targeting construct is linearized at a site within the homology region using a restriction enzyme, electroporated into cells, and positively selected to isolate homologous recombinants. These homologous recombinants contain local repeats separated by intermediate vector sequences, including a selection cassette. In the second step, negative selection is performed on the target clone to identify cells that have lost the selection cassette through recombination within the chromosome between the repeated sequences. The local recombination event removes the repeat, and depending on the site of recombination, the allele retains the introduced mutation, or reverts to the wild type. The end result is the introduction of the desired modification without retaining any exogenous sequence.
[0126] "Double-replacement" or "tag and exchange" strategy - involves a two-step selection procedure similar to the hit and run method, but requires the use of two different targeting constructs. In the first step, a standard targeting vector with 3' and 5' homology arms is used to insert a dual positive / negative selection cassette near the position where the mutation is to be introduced. After electroporation and positive selection, homologous targeted clones are identified. Next, a second targeting vector containing a region of homology to the desired mutation is electroporated into the targeted clone, and negative selection is applied to remove the selection cassette and introduce the mutation. The final allele contains the desired mutation while eliminating the unwanted exogenous sequence.
[0127] Site-specific recombinases - Cre recombinase from P1 bacteriophage and Flp recombinase from yeast Saccharomyces cerevisiae are site-specific DNA recombinases that each recognize a unique 34 base pair DNA sequence (referred to as "Lox" and "FRT", respectively) and can easily remove sequences flanked by Lox sites or FRT sites by site-specific recombination when Cre or Flp recombinase is expressed, respectively. For example, the Lox sequence consists of an asymmetric 8 base pair spacer flanked by 13 base pair inverted repeats. Cre recombines the 34 base pair lox DNA sequence by binding to the 13 base pair inverted repeats and catalyzing strand cleavage and rejoining within the spacer. The staggered DNA cuts made by Cre in the spacer are separated by 6 base pairs, forming an overlap region that acts as a homology sensor to ensure that only recombination sites with identical overlap regions can recombine.
[0128] Basically, the site-specific recombinase system provides a method for removing the selection cassette after homologous recombination. This system also allows the generation of conditionally altered alleles that can be inactivated or activated in a temporal or tissue-specific manner. It is worth noting that the Cre and Flp recombinases leave a 34 base pair Lox or FRT "scar". The remaining Lox or FRT sites are usually left in the introns or 3'UTR of the modified site, and current evidence suggests that such sites usually do not significantly interfere with gene function.
[0129] Therefore, Cre / Lox and Flp / FRT recombination involves the introduction of a targeting vector with 3' and 5' homology arms containing the mutation of interest, two Lox or FRT sequences, and a selectable cassette typically located between the two Lox or FRT sequences. Positive selection is applied and homologous recombinants containing the targeted mutation are identified. Transient expression of Cre or Flp combined with negative selection results in excision of the selection cassette and selection of cells in which the cassette has been lost. The final targeted allele contains a Lox or FRT scar of the exogenous sequence.
[0130] Transposase - As used herein, the term "transposase" refers to an enzyme that binds to the end of a transposon and catalyzes the movement of the transposon to another part of the genome.
[0131] As used herein, the term "transposon" refers to a mobile genetic element comprising a nucleotide sequence that can move to different locations within the genome of a single cell. In the process, the transposon can cause mutations and / or change the amount of DNA in the genome of the cell.
[0132] Many transposon systems capable of transposition in cells, such as vertebrates, have been isolated or engineered, such as Sleeping Beauty [Iswak and Avicius, Molecular Therapy (2004) 9, 147-156], piggyBac [Wilson et al., Molecular Therapy (2007) 15, 139-145], Tol2 [Kawakami et al., PNAS (2000) 97 (21): 11403-11408] or Frog Prince [Miski et al., Nucleic Acids Res. Dec 1, (2003) 31 (23): 6873-6881]. Generally, DNA transposons are transferred from one DNA site to another DNA site in a simple cut-and-paste manner. Each of these elements has its advantages, for example, Sleeping Beauty is particularly useful in region-specific mutagenesis, while Tol2 is most likely to integrate into expressed genes. Superactive systems can be used for Sleeping Beauty and piggyBac. Most importantly, these transposons have different target site preferences and can therefore introduce sequence changes in overlapping, but different genomes. Therefore, in order to achieve optimal gene coverage, it is particularly preferred to use multiple elements. The basic mechanism is shared between different transposases, so we will use piggyBac (PB) as an example.
[0133] PB is a 2.5 kb insect transposon originally isolated from Trichoplusia ni. The PB transposon consists of asymmetric terminal repeats on either side of a transposase. PBase recognizes the terminal repeats and induces transposition via a "cut-and-paste" mechanism, preferentially transposing into the host genome at the tetranucleotide sequence TTAA. After insertion, the TTAA target site is replicated so that the tetranucleotide sequence is present on both sides of the PB transposon. When moved, the PB typically precisely excises itself to reestablish a single TTAA site, thereby restoring the host sequence to its pre-transposon state. After excision, the PB can transpose to a new location or permanently disappear from the genome.
[0134] Typically, the transposase system provides an alternative method for removing the selection box after homologous recombination, similar to the use of Cre / Lox or Flp / FRT. Thus, for example, the PB transposase system involves the introduction of a targeting vector with 3' and 5' homology arms, the homology arms comprising the mutation of interest, two PB terminal repeats at the site of an endogenous TTAA sequence, and a selection box between the PB terminal repeats. Positive selection is applied and homologous recombinants comprising targeted mutations are identified. The transient expression of PBase combined with negative selection can result in the excision of the selection box, and cells in which the box has been lost are selected. The final targeted allele comprises the introduced mutation without exogenous sequences.
[0135] In order for PB to be useful for introducing sequence changes, there must be a natural TTAA site present relatively close to the location of the particular mutation to be inserted.
[0136] Genome editing using a recombinant adeno-associated virus (rAAV) platform - This genome editing platform is based on rAAV vectors, which are capable of inserting, deleting or replacing DNA sequences in the genome of living mammalian cells. The rAAV genome is a single-stranded deoxyribonucleic acid (ssDNA) molecule, either a positive or negative strand, and is approximately 4.7 kb long. These single-stranded DNA viral vectors have high transduction rates and have the unique property of stimulating endogenous homologous recombination in the absence of double-stranded DNA breaks in the genome. Those skilled in the art can design rAAV vectors to target a desired genomic site and make significant and / or subtle endogenous gene changes in a cell. The advantage of rAAV genome editing is that it targets a single allele and does not cause any off-target genomic changes. rAAV genome editing technology is commercially available, for example, from Horizon TM rAAV GENESIS (Cambridge, UK) TM system.
[0137] It will be appreciated that the agent may be a mutagen which causes random mutations, and cells which exhibit down-regulation of target expression levels and / or activity may be selected.
[0138] The mutagen may be, but is not limited to, a genetic, chemical, or radiation agent. For example, the mutagen may be ionizing radiation, such as, but not limited to, ultraviolet light, gamma rays, or alpha particles. Other mutagens may include, but are not limited to, base analogs, which may cause replication errors; deaminating agents, such as nitrous acid; intercalating agents, such as ethidium bromide; alkylating agents, such as bromouracil; transposons; natural and synthetic alkaloids; bromine and its derivatives; sodium azide; psoralen (e.g., combined with ultraviolet radiation). The mutagen may be a chemical mutagen, such as, but not limited to, ICR191, 1,2,7,8-diepoxy-octane (DEO), 5-azaC, N-methyl-N-nitrosoguanidine (MNNG), or ethyl methane sulfonate (EMS).
[0139] Methods for identifying efficacy and detecting sequence changes are well known in the art and include, but are not limited to, DNA sequencing, electrophoresis, enzyme-based mismatch detection assays, and hybridization assays such as PCR, RT-PCR, RNase protection, in situ hybridization, primer extension, Southern blotting, Northern blotting, and dot blot analysis.
[0140] Sequence changes in a particular gene may also be determined at the protein level using, for example, chromatography, electrophoresis, immunodetection assays such as ELISA and Western blot analysis, and immunohistochemistry.
[0141] In addition, those of ordinary skill in the art can easily design knock-in / knock-out constructs including positive and / or negative selection markers to effectively select transformed cells with homologous recombination events occurring with the construct. Positive selection provides a method to enrich the clone population that has absorbed foreign DNA. Non-limiting examples of such positive markers include glutamine synthetase, dihydrofolate reductase (DHFR), markers that confer antibiotic resistance, such as neomycin, hygromycin, puromycin, and blasticide S resistance box. Negative selection markers are necessary for selecting random integration and / or elimination of marker sequences (e.g., positive markers). Non-limiting examples of such negative markers include herpes simplex-thymidine kinase (HSV-TK), hypoxanthinephosphoribosyltransferase (HPRT), and adeninephosphoribosyltransferase (ARPT), which convert ganciclovir (GCV) into a cytotoxic nucleoside analog.
[0142] Down-regulation at the peptide level:
[0143] According to one embodiment, the agent capable of downregulating P-selectin is an antibody or antibody fragment capable of specifically binding to and inhibiting P-selectin.
[0144] Preferably, the antibody specifically binds to at least one epitope of P-selectin.
[0145] In another embodiment, the agent is an antibody or antibody fragment that is capable of specifically binding to and inhibiting PSGL-1.
[0146] Preferably, the antibody specifically binds to at least one epitope of PSGL-1.
[0147] As used herein, the term "epitope" refers to any antigenic determinant on an antigen to which the paratope of an antibody binds. Epitope determinants are usually composed of chemically active surface groups of molecules, such as amino acids or carbohydrate side chains, and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics.
[0148] Methods for producing polyclonal and monoclonal antibodies and fragments thereof are well known in the art (see, e.g., Harlow and Ryan, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference).
[0149] The term "antibody" as used in the present invention includes intact molecules and functional fragments thereof (which are capable of binding to an epitope of an antigen).
[0150] As used herein, the term "epitope" refers to any antigenic determinant on an antigen to which the paratope of an antibody binds. Epitope determinants are usually composed of chemically active surface groups of molecules, such as amino acids or carbohydrate side chains, and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics.
[0151] According to a specific embodiment, antibody fragments include, but are not limited to, single chains, Fab, Fab' and F(ab')2 fragments, Fd, Fcab, Fv, dsFv, scFvs, diabodies, miniantibodies, nanoantibodies, Fab expression libraries or single domain molecules capable of binding to an epitope of an antigen in an HLA-restricted manner, such as VH and VL.
[0152] Antibody fragments suitable for practicing some embodiments of the present invention include complementarity-determining regions (CDRs) of immunoglobulin light chains (referred to herein as "light chains"), complementarity-determining regions of immunoglobulin heavy chains (referred to herein as "heavy chains"), variable regions of light chains, variable regions of heavy chains, light chains, heavy chains, Fd fragments, and antibody fragments that substantially contain the entire variable regions of both light and heavy chains, such as Fv, single-chain Fv Fv (scFv), disulfide-stabilized Fv (dsFv), Fab, Fab' and F(ab')2, or contain the Fc region of an antibody.
[0153] As used herein, the term "complementarity-determining region" or "CDR" is used interchangeably and refers to the antigen binding region within the variable region of the heavy and light chain polypeptides. Typically, an antibody comprises three CDRs in each VH (CDR HI or HI; CDR H2 or H2; and CDR H3 or H3) and three CDRs in each VL (CDR LI or LI; CDR L2 or L2; and CDR L3 or L3).
[0154] The identity of the amino acid residues that make up the variable region or CDR in a particular antibody can be determined using methods known in the art and include methods such as the sequence variability defined by Kabat et al. (see, e.g., Kabat et al., 1992, Sequences of Proteins of Immunological Interest, 5th Ed., Public Health Service, National Institutes of Health, Washington, D.C.), the location of the structural loop regions defined by Josiah et al. (see, e.g., Josiah et al., Nature, 342:877-883, 1989), a compromise between Kabat and Josiah using Oxford Molecular's AbM antibody modeling software (now known as See, Martin et al., 1989, Proc. Natl Acad Sci USA. 86:9268; and the World Wide Web website www.bioinf-org.uk / abs), available complex crystal structures defined by contact definitions (see McCallum et al., J. Mol. Biol. 262:732-745, 1996) and "conformational definitions" (see, e.g., Makabe et al., Journal of Biological Chemistry, 283:1156-1166, 2008).
[0155] As used herein, "variable region" and "CDR" may refer to variable regions and CDRs defined by any method known in the art, including a combination of methods.
[0156] Functional antibody fragments comprising the entire or substantially the entire variable region of a light chain and a heavy chain are defined as follows:
[0157] (i) Fv, defined as a genetically engineered fragment consisting of the variable region of the light chain (VL) and the variable region of the heavy chain (VH), represented by two chains;
[0158] (ii) Single-chain Fv ("scFv"), a genetically engineered single-chain molecule comprising a light chain variable region and a heavy chain variable region, connected by a suitable polypeptide linker as a genetically fused single-chain molecule.
[0159] (iii) disulfide-stabilized Fv ("dsFv"), a genetically engineered antibody comprising a light chain variable region and a heavy chain variable region connected by a genetically engineered disulfide bond.
[0160] (iv) Fab, a fragment of an antibody molecule, comprising a monovalent antigen-binding portion of an antibody molecule, which can be obtained by treating the whole antibody with papain to obtain a complete light chain and a heavy chain Fd fragment, which is composed of its variable domain and CH1 domain;
[0161] (v) Fab', a fragment of an antibody molecule comprising a monovalent antigen-binding portion of an antibody molecule, which can be obtained by treating whole antibody with pepsin followed by reduction (two Fab' fragments are obtained for each antibody molecule);
[0162] (vi) F(ab')2, a fragment of an antibody molecule comprising a monovalent antigen-binding portion of an antibody molecule, which can be obtained by treating a whole antibody with pepsin (i.e., a dimer of Fab' fragments held together by two disulfide bonds);
[0163] (vii) Single domain antibodies or Nanobodies are composed of a single VH or VL domain that has sufficient affinity for the antigen; and
[0164] (viii) Fcab, a fragment of an antibody molecule, comprises the Fc portion of an antibody and is developed as an antigen binding domain by introducing antigen binding ability into the Fc region of an antibody.
[0165] Methods for producing polyclonal and monoclonal antibodies and fragments thereof are well known in the art (see, e.g., Harlow and Ryan, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference).
[0166] Exemplary methods for producing antibodies employ induction of antibody molecules in vivo, screening of immunoglobulin libraries (Orlandi DR et al., 1989, Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter G et al., 1991, Nature 349:293-299) or production of monoclonal antibody molecules by continuous cell lines in culture. These include, but are not limited to, hybridoma technology, human B cell hybridoma technology, and Epstein-Barr virus (EBV) hybridoma technology (Kohler G. et al., 1975, Nature 256:495-497; Kozibor D. et al., 1985, J. Immunol. Methods 81:31-42; Cote RJ. et al., 1983, Proc. Natl. Acad. Sci. USA 80:2026-2030; Cole SP. et al., 1984, Mol. Cell. Biol. 62:109-120).
[0167] If the target antigen is too small to elicit a sufficient immunogenic response when antibodies are produced in vivo, such antigens (haptens) can be coupled to an antigen neutral carrier, such as a keyhole limpet hemocyanin (KLH) or serum albumin [e.g., bovine serum albumin (BSA)] carrier (see, e.g., U.S. Pat. Nos. 5,189,178 and 5,239,078). The hapten can be coupled to the carrier using methods known in the art. For example, coupling can be done directly to an amino group, and the resulting imino bond can then be optionally reduced. Alternatively, a condensing agent, such as dicyclohexylcarbodiimide or other carbodiimide dehydrating agents, can be used to couple the carrier. Linker compounds can also be used for coupling; both homobifunctional linkers and heterobifunctional linkers are available from Pierce Chemical Company, Rockford, Illinois. The resulting immunogenic complex can then be injected into a suitable mammalian subject, such as a mouse, rabbit, etc. A suitable regimen involves repeated injections of the immunogen on a schedule in the presence of an adjuvant to promote the production of antibodies in the serum.The titer of the immune serum can be readily measured using immunoassay procedures well known in the art.
[0168] The antiserum obtained can be used directly, or monoclonal antibodies can be obtained as described above.
[0169] According to some embodiments of the invention, antibody fragments can be prepared by proteolysis of the antibody or by expressing DNA encoding the fragments in E. coli or mammalian cells (eg, Chinese hamster ovary cell culture or other protein expression systems).
[0170] Antibody fragments can be obtained by digesting whole antibodies with pepsin or papain by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted as F(ab')2. This fragment can be further cleaved using a thiol reducing agent, and optionally a group that blocks the sulfhydryl groups produced by the cleavage of disulfide bonds, to produce a 3.5S Fab' monovalent fragment. Alternatively, enzymatic cleavage using pepsin directly produces two monovalent Fab' fragments and an Fc fragment. Such methods are described in, for example, U.S. Pat. Nos. 4,036,945 and 4,331,647 to Goldenberg, and the references contained therein, which are hereby incorporated by reference in their entirety. See also Porter, RR [Biochem. J. 73: 119-126 (1959)]. Other methods of cleaving antibodies can also be used, such as separating heavy chains to form monovalent light and heavy chain fragments, further cleaving fragments or other enzymes, chemicals or genetic techniques, as long as the fragments bind to the antigen recognized by the intact antibody.
[0171] As described above, the Fv fragment comprises a combination of a VH chain and a VL chain. This combination may be non-covalent, as described by Inbar et al. [Proc. Nat'l Acad. Sci. USA 69: 2659-62 (19720). Alternatively, the variable chains may be linked by intermolecular disulfide bonds or cross-linked by a chemical such as glutaraldehyde. Preferably, the Fv fragment comprises a VH chain and a VL chain linked by a peptide linker. Such single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising a DNA sequence encoding a VH domain and a VL domain linked by an oligonucleotide. The structural gene is inserted into an expression vector, which is then introduced into a host cell such as E. coli. The recombinant host cell synthesizes a single polypeptide chain in which a linker peptide connects the two V domains. Methods for producing sFv are described, for example, in [Whitlow and Filpura, Methods 2:97-105 (1991); Bird et al., Science 242:423-426 (1988); Park et al., Bio / Technology 11:1271-77 (1993); and U.S. Pat. No. 4,946,778, the entire contents of which are incorporated herein by reference.
[0172] Another form of antibody fragment is a peptide encoding a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing a gene encoding the CDR of an antibody of interest. For example, such genes are prepared by synthesizing the variable region from RNA of antibody-producing cells using the polymerase chain reaction. See, for example, Larrick and Fry [Methods, 2: 106-10 (1991)].
[0173] As previously described, an antibody fragment may include the Fc region of an antibody, referred to as an "Fcab". Such an antibody fragment generally includes the CH2-CH3 domain of an antibody. Fcabs are designed to include at least one modification in the structural loop region of the antibody, i.e., in the CH3 region of the heavy chain. Such an antibody fragment may be produced, for example, in the following manner: providing a nucleic acid encoding an antibody comprising at least one structural loop region (e.g., an Fc region), modifying at least one nucleotide residue in at least one structural loop region, transferring the modified nucleic acid to an expression system, expressing the modified antibody, contacting the expressed modified antibody with an epitope, and determining whether the modified antibody binds to the epitope. See, e.g., U.S. Pat. Nos. 9,045,528 and 9,133,274, which are incorporated herein by reference in their entirety.
[0174] Humanized forms of non-human (e.g., mouse) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains, or fragments thereof (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding subsequences of antibodies) that contain minimal sequences derived from non-human immunoglobulins. Humanized antibodies include human immunoglobulins (recipient antibodies) in which residues in the complementary determining regions (CDRs) of the receptor are replaced by residues from CDRs of non-human species (donor antibodies) having the desired specificity, affinity, and capacity, such as mice, rats, or rabbits. In some cases, Fv framework residues of human immunoglobulins are replaced by corresponding non-human residues. Humanized antibodies may also include residues that are not present in either the recipient antibody or the imported CDR or framework sequences. In general, humanized antibodies will include substantially all of at least one, usually two, variable domains, wherein all or substantially all of the CDR regions correspond to the CDR regions of non-human immunoglobulins, and all or substantially all of the FR regions are FR regions of human immunoglobulin consensus sequences. The humanized antibody optimally will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Richman et al., Nature, 332:323-329 (1988); and Priestad, Curr. Op. Struct. Biol., 2:593-596 (1992)].
[0175] Methods for humanizing non-human antibodies are well known in the art. Generally, humanized antibodies have one or more amino acid residues introduced from a non-human source. These non-human amino acid residues are usually referred to as import residues, which are usually taken from an import variable domain. Humanization can be performed essentially according to the method of Winter et al. [Jones et al., Nature, 321: 522-525 (1986); Richman et al., Nature 332: 323-327 (1988); Verhoyen et al., Science, 239: 1534-1536 (1988)] by replacing the corresponding sequence of a human antibody with a rodent CDR or CDR sequence. Therefore, such humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), in which a portion of a significantly less than complete human variable domain is replaced by a corresponding sequence from a non-human species. In practice, humanized antibodies are usually human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
[0176] Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marx et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Berner et al. can also be used to prepare human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Berner et al., J. Immunol., 147(1): 86-95 (1991)]. Similarly, human antibodies can be prepared by introducing human immunoglobulin loci into transgenic animals, for example, mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon stimulation, production of human antibodies is observed that closely resemble those seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This method is described, for example, in U.S. Pat. Nos. 5,545,807, 5,545,806, 5,569,825, 5,625,126, 5,633,425; 5,661,016, and in the following scientific publications: Marx et al., Bio / Technology. 10:779-783 (1992); Lomborg et al., Nature 368:856-859 (1994); Morrison, Nature 368 812-13 (1994); Fishwell et al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14:826 (1996); and Lomborg and Hussar, Intern. Rev. Immunol. 13, 65-93 (1995).
[0177] The antibodies described herein can be conjugated to a therapeutic moiety. The therapeutic moiety can be, for example, a cytotoxic moiety, a toxic moiety, a cytokine moiety, and a second antibody moiety comprising a different specificity than the antibody of the invention.
[0178] Table 1 below provides non-limiting examples of therapeutic moieties that can be conjugated to the antibodies of the invention.
[0179] Table 1
[0180]
[0181] Other therapeutic moieties that can be attached to the antibodies of the invention include anti-cancer agents, such as chemotherapeutic agents, including but not limited to tubulin inhibitors, such as exatecan, belotecan, entansine, and the like.
[0182] Therapeutic moieties can be attached or bound to the antibodies of the invention in various ways, depending on the context, application and purpose.
[0183] When the functional part is a polypeptide, the immunoconjugate can be produced by recombinant means. For example, a nucleic acid sequence encoding a toxin (e.g., PE38KDEL) or a fluorescent protein [e.g., green fluorescent protein (GFP), red fluorescent protein (RFP) or yellow fluorescent protein (YFP)] can be linked in frame with a nucleic acid sequence encoding an antibody of the invention and expressed in a host cell to produce a recombinant binding antibody. Alternatively, the functional part can be synthesized chemically, for example, by stepwise addition of one or more amino acid residues in a determined order, such as solid phase peptide synthesis techniques.
[0184] Functional moieties can also be linked to the antibodies of the invention using standard chemical synthesis techniques widely practiced in the art [see, e.g., hypertext transfer protocol: / / worldwideweb.chemistry.org / portal / Chemistry)], for example, using any suitable chemical linkage, directly or indirectly, such as via a peptide bond (when the functional moiety is a polypeptide), or by covalent bonding to an intermediate linking element, such as a linker peptide or other chemical moiety, such as an organic polymer. Chimeric peptides can be linked by bonding at the carboxyl (C) or amino (N) termini of the peptide, or by bonding to internal chemical groups, such as linear, branched or cyclic side chains, internal carbon or nitrogen atoms, etc. U.S. Patents Nos. 3,940,475, 4,289,747 and 4,376,110 describe fluorescent labeling of antibodies in detail.
[0185] Exemplary methods of conjugating a peptide moiety (therapeutic or detectable moiety) to an antibody of the invention are described below:
[0186] SPDP conjugation - A non-limiting example of a method for SPDP conjugation is described by Campbell et al. (1985, Methods of Enzymology, 112: 207-224). Briefly, a peptide, e.g., a detectable or therapeutic moiety (e.g., 1.7 mg / ml) is mixed with a 10-fold excess of SPDP (50 mM in ethanol); the antibody is mixed with a 25-fold excess of SPDP in 20 mM sodium phosphate, 0.10 M NaCl pH 7.2, and each reaction is incubated at room temperature for about 3 hours. The reaction is then dialyzed against PBS. The peptide is reduced, e.g., using 50 mM DTT for 1 hour at room temperature. The reduced peptide is desalted on a G-25 column using 50 mM KH2PO4 pH 6.5 by equilibration (up to 5% sample / column volume). The reduced peptide is combined with the SPDP antibody at a molar ratio of 1:10 antibody:peptide and incubated overnight at 4°C to form the peptide-antibody conjugate.
[0187] Glutaraldehyde conjugation - A non-limiting example of a glutaraldehyde conjugation method is described in GT. Hermansson (1996, "Antibody modification and conjugation", in Bioconjugate Techniques, Academic Press, San Diego). Briefly, the antibody and peptide (1.1 mg / ml) are mixed with 0.05% glutaraldehyde in 0.1 M phosphate, 0.15 M NaCl pH 6.8 in a 10-fold excess and reacted at room temperature for 2 hours. 0.01 M lysine may be added to block excess sites. After the reaction, excess glutaraldehyde is removed using a G-25 column (10% v / v sample / column volume) equilibrated with PBS.
[0188] Carbodiimide coupling - The conjugation of peptides to antibodies can be accomplished using a dehydrating agent such as carbodiimide, for example, in the presence of 4-dimethylaminopyridine. Carbodiimide conjugation can be used to form a covalent bond between the carboxyl group of the peptide and the hydroxyl group of the antibody (thereby forming an ester bond), or to form a covalent bond between the amino group of the antibody (thereby forming an amide bond), or to form a covalent bond between the sulfhydryl group of the antibody (thereby forming a thioester bond). Similarly, carbodiimide conjugation can be used to form similar covalent bonds between the carbon group of the antibody and the hydroxyl, amino or sulfhydryl group of the peptide [see, J. March, Advanced Organic Chemistry: Reaction's, Mechanism, and Structure, pp. 349-50 and 372-74 (3rd ed.), 1985]. For example, a carbodiimide (eg, dicyclohexylcarbodiimide) can be used to bind the peptide to the antibody via a covalent bond [B. Nice et al. (1978), Angew Chem., Int. Ed. Engl. 17:522; A. Hasner et al. (1978, Tetrahedron Lett. 4475); EP Boden et al. (1986, J. Org. Chem. 50:2394) and LJ Mathias (1979, Synthesis 561)].
[0189] According to another embodiment, the antibodies described herein are not conjugated to a therapeutic or diagnostic moiety.
[0190] Another agent that can be used with some embodiments of the present invention to downregulate P-selectin is an aptamer. As used herein, the term "aptamer" refers to a double-stranded or single-stranded RNA molecule that binds to a specific molecular target, such as a protein. Various methods are known in the art that can be used to design protein-specific aptamers. A skilled person can use SELEX (systematic evolution of ligands by exponential enrichment) to perform efficient selection, as described in Stoltenberg R, Reinemann C, and Strelitz B (Biomolecular engineering (2007) 24 (4): 381-403).
[0191] Another agent capable of downregulating P-selectin is any molecule that binds to and / or cleaves P-selectin. Such a molecule may be a small molecule, a P-selectin antagonist, or a P-selectin inhibitory peptide.
[0192] Another prospective drug that can be used to downregulate P-selectin includes a proteolysis-targeting chimaera (PROTAC). Such drugs are heterobifunctional, including a ligand that binds to a ubiquitin ligase (e.g., an E3 ubiquitin ligase) and a ligand that binds to P-selectin, and a linker that optionally connects the two ligands. Binding of PROTAC to the target protein results in ubiquitination of the exposed lysines on the target protein, followed by protein degradation mediated by the ubiquitin proteasome system (UPS).
[0193] In one embodiment, the P-selectin inhibitor is a monoclonal antibody against P-selectin, such as crizanlizumab or inclacumab. These antibodies against P-selectin are developed for the treatment of sickle cell anemia and myocardial damage after a heart attack, respectively. Both antibodies are well tolerated by patients when administered systemically.
[0194] According to a specific embodiment, the P-selectin inhibitor is a monoclonal antibody directed against PSLGL-1. An example of such an antibody is VTX-0811, which is being developed by Verseau Therapeutics (www.verseautx.com / pipeline).
[0195] In another embodiment, the P-selectin inhibitor is a small molecule, such as rivipansel or tinzaparin, which are being developed for the treatment of sickle cell anemia and as an anticoagulant, respectively. Rivipansel is not specific for P-selectin but inhibits several members of the selectin family. Tinzaparin is a heparin analog.
[0196] In another embodiment, the P-selectin inhibitor is KF 38789 (3-[7-(2,4-dimethoxyphenyl)-2,3,6,7-tetrahydro-1,4-thiazepin-5-yl]-4-hydroxy-6-methyl-2H-pyran-2-one) produced by Tocris.
[0197] Additional exemplary P-selectin inhibitors are summarized in Table 2 below.
[0198]
[0199]
[0200] 1. Ataga, KI, et al., Crazanlizumab for preventing pain crises in sickle cell disease. N Engl J Med, 2017.
[0201] 376(5): pp. 429-439.
[0202] 2. Beida, PW, et al. Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J Pharmacol Exp Ther, 2008. 324(2): 497-506.
[0203] 3. Park, IY, et al., Cylexin: a P-selectin inhibitor prolongs cardiac allograft survival in allergic rat recipients. Transplant Proc, 1998. 30(7): pp. 2927-8.
[0204] 4. Mayer, FB, et al., Effects of the pan-selectin antagonist bimosiamose (TBC1269) on experimental human endotoxemia. Shock, 2008, 29(4): 475-82.
[0205] 5. Zhang, J., et al., The novel pan-selectin antagonist GMI-1070 reverses acute vascular occlusion in sickle cell mice. Blood,
[0206] 2010, 116(10): pp. 1779-86.
[0207] Agents useful for downregulating the amount and / or activity of P-selectin may be formulated to cross the blood-brain barrier.
[0208] Yeini et al., Advanced Therapeutic, DOI: 10.1002 / adtp.202000124, describe exemplary methods for formulating the above-mentioned agents to enhance their crossing of the blood-brain barrier.
[0209] Thus, for example, the agent can be formulated as nanoparticles, such as liposome-based nanoparticles, amphiphilic micelles, dendrimers, inorganic nanoparticles, and polymeric nanoparticles.
[0210] Specifically, for the delivery of oligonucleotides, biodegradable poly(β-amino ester) (PBAE) modified with cationic nanoemulsions, cell-derived extracellular vesicles, and spherical nucleic acid nanoparticles can be considered to improve delivery to the brain.
[0211] Since the BBB restricts most therapeutic agents from entering the brain from the blood, receptor-mediated transcytosis can provide a non-invasive transport system to deliver targeted vectors into the brain parenchyma. In addition, this approach allows for selective targeting of tumor cells within brain tissue, thereby reducing toxicity to other tissues and non-tumor cells in the brain. Examples of receptor-mediated approaches include manipulation of apolipoprotein receptors, targeting of epidermal growth factor receptors, transferrin receptor targeting, insulin receptor targeting, and adhesion molecule targeting.
[0212] It will be appreciated that the P-selectin inhibitor may be attached directly to a moiety that targets the agent to the blood-brain barrier, or indirectly (eg, the P-selectin inhibitor may be included in a carrier that is attached to the targeting moiety).
[0213] According to one aspect of the invention, a P-selectin inhibitor is used (in combination with an immunomodulator) to treat brain metastases.
[0214] Metastatic brain cancer (also called secondary brain tumors) is caused by cancer cells spreading (metastasizing) from other parts of the body to the brain.
[0215] According to one embodiment, the brain metastatic cancer is selected from the group consisting of
[0216] As previously mentioned, P-selectin inhibitors can be administered / co-formulated with immunomodulators. In one embodiment, the immunomodulator is a nanoparticle comprising a neoantigenic peptide (e.g., GL261) for glioblastoma. Methods for preparing such nanoparticles are disclosed in WO2020 / 136657, the contents of which are incorporated herein by reference.
[0217] In one embodiment, the immunomodulator is a checkpoint inhibitor.
[0218] The term "checkpoint blockade" or "checkpoint inhibitor" refers to an immunotherapy, meaning that it is intended to help the patient's own immune system fight cancer. It can use substances such as monoclonal antibodies or their binding fragments, which can be designed to target extremely specific molecules on the surface of cells. For example, antibodies can relieve the immune system's natural attack on invading cancer cells. In another example, the ligand-receptor interaction that has been studied as a target for cancer treatment is the interaction between the transmembrane programmed cell death 1 protein (programmed cell death 1protein, PDCD1, PD-1; also known as CD279) and its ligand, PD-1 ligand 1 (PD-L1, CD274). In normal physiology, PD-L1 on the surface of cells binds to PD1 on the surface of immune cells, thereby inhibiting the activity of immune cells. The upregulation of PD-L1 displayed on the surface of cancer cells can evade the host immune system by inhibiting T cells that may attack tumor cells. Antibodies that bind to PD-1 or PD-L1 and thus block the interaction can enable T cells to attack tumors. In some alternatives, the checkpoint blockade therapy comprises an anti-PD-1 antibody or a binding fragment thereof (e.g., a monoclonal antibody or a humanized version thereof or a binding fragment thereof). In some alternatives, the checkpoint blockade therapy comprises PD-L1.
[0219] Examples of immunomodulators include immunomodulatory cytokines, including but not limited to IL-2, IL-15, IL-7, IL-21, GM-CSF, and any other cytokine that can further enhance the immune response; immunomodulatory antibodies, including but not limited to anti-CTLA4, anti-CD40, anti-41BB, anti-OX40, anti-PD1, and anti-PDL1; and immunomodulatory drugs, including, but not limited to, lenalidomide (Revlimid).
[0220] Exemplary anti-PD1 antibodies include Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), and Dostarlimab (Jemperli).
[0221] According to a specific embodiment, the anti-PD1 antibody is nivolumab.
[0222] Other anti-PD1 antibodies include JTX-4014, Spartalizumab (PDR001), Camrelizumab (SHR1210), Sintilimab (IBI308), Tislelizumab (BGB-A317), Toripalimab (JS 001) INCMGA00012 (MGA012), AMP-224AMP-514 (MEDI0680).
[0223] Other contemplated anticancer agents that may be administered to a subject in combination with the P-selectin inhibitors described herein include, but are not limited to, Acivicin; Aclarubicin; Acodazole Hydrochloride; Acronine; Adriamycin; Adozelesin; Aldesleukin; Altretamine; Ambomycin; Ametantrone Acetate; Acetate; aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin; Azetepa; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide hydrochloride; Bisantrene Hydrochloride; Bisnafide Dimesylate; Bizelesin; Bleomycin Sulfate; Brequinar Sodium Sodium; Bropirimine; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin; Cisplatin; Cladribine; Crisnatol Mesylate; Mesylate; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine;Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate; Eflornithine Hydrochloride; Elsamitrucin; Enloplatin; Enpromate; Epipropidine; Epirubicin Hydrochloride Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine; Estramustine Phosphate Sodium; Etanidazole; Etoposide; Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil; Fluorocitabine; Fosquidone; Fostriecin Sodium Sodium; Gemcitabine; Gemcitabine Hydrochloride; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofosine; Interferon α-2a; Interferon α-2b; Interferon α-n1; Interferon α-n3; Interferon β-I a; Interferon γ-I b; Iproplatin;Irinotecan Hydrochloride; Lanreotide Acetate; Letrozole; Leuprolide Acetate; Liarozole Hydrochloride; Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride; Masoprocol; Maytansine; Mechlorethamine Hydrochloride; Megestrol Acetate; Melengestrol Acetate; Melphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium Sodium; Metoprine; Meturedepa; Mitindomide; Mitocarcin; Mitocromin; Mitogillin; Mitomalcin; Mitomycin; Mitosper; Mitotane; Mitoxantrone Hydrochloride; Mycophenolic Acid; Nocodazole; Nogalamycin; Ormaplatin; Oxisuran; Paclitaxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin Sulfate Sulfate; Perfosfamide; Pipobroman; Piposulfan; Piroxantrone Hydrochlorid; Plicamycin; Plomestane; Porfimer Sodium; Porfiromycin; Prednimustine;Procarbazine Hydrochloride; Puromycin; Puromycin Hydrochloride; Pyrazofurin; Riboprine; Rogletimide; Safingol; Safingol Hydrochloride; Semustine; Simtrazene; Sparrosate Sodium; Sparsomycin; Spirogermanium Hydrochloride Hydrochloride; Spiromustine; Spiroplatin; Streptonigrin; Streptozocin; Sulofenur; Talisomycin; Taxol; Tecogalan Sodium; Tegafur; Teloxantrone Hydrochloride; Temoporfin; Teniposide; Teroxirone; Testolactone; Thiamiprine; Thioguanine; Thiotepa; Tiazofuirin; Tirapazamine; Topotecan Hydrochloride; Hydrochloride; Toremifene Citrate; Trestolone Acetate; Triciribine Phosphate; Trimetrexate; Trimetrexate Glucuronate; Triptorelin; Tubulozole Hydrochloride; Uracil Mustard; Uredepa; Vapreotide; Verteporfin; Vinblastine Sulfate; Vincristine Sulfate; Vindesine;Vindesine Sulfate; Vinepidine Sulfate; Vinglycinate Sulfate; Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine Sulfate; Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin; Zorubicin Hydrochloride. Other antineoplastic agents include those disclosed in Goodman and Gilman, "The Pharmacological Basis of Therapeutics", 8th edition, 1990, McGraw-Hill Companies (Health Professionals Division), Chapter 52, "Antineoplastic Agents" (Paul Calabresi and Bruce A. Chabner), and the introduction thereto, pp. 1202-1263. ;
[0224] Examples of cancer include, but are not limited to, malignancies, lymphomas, blastomas, sarcomas, and leukemias. Specific examples of cancer diseases include, but are not limited to: myeloid leukemias, such as chronic myeloid leukemia. Acute myeloid leukemia mature. Acute promyelocytic leukemia, acute non-lymphocytic leukemia with basophilia, acute monocytic leukemia. Acute myelomonocytic leukemia with eosinophilia; malignant lymphomas, such as Birkitt's Non-Hodgkin's; lymphocytic leukemias, such as acute lymphoblastic leukemia. Chronic lymphocytic leukemia; myeloproliferative disorders, such as solid tumors benign meningioma, mixed tumors of the salivary glands, colon adenomas; adenocarcinomas, such as small cell lung cancer, kidney cancer, uterine cancer, prostate cancer, bladder cancer, ovarian cancer, colon cancer, sarcoma, liposarcoma, myxoid sarcoma, synovial sarcoma, rhabdomyosarcoma (alveolar), extraskeletal myxoid chondrosarcoma, Ewing's sarcoma; others include testicular and ovarian dysgerminoma, retinoblastoma, Wilms' tumor, neuroblastoma, malignant melanoma, mesothelioma, breast cancer, skin cancer, prostate cancer and ovarian cancer.
[0225] According to a specific embodiment, the cancer is a solid tumor.
[0226] Exemplary cancers that may be treated using combination therapy (ie, immunomodulator + P-selectin inhibitor) include pancreatic cancer, lung cancer, breast cancer, primary melanoma, and renal cancer.
[0227] P-selectin inhibitors may be co-formulated with the immunomodulators described herein, or provided to a subject as a separate composition.
[0228] Thus, the various agents included in the combination may be formulated separately for use in combination. When the effect of one drug enhances or at least affects the effect of the other drug in the recipient of the two drugs, the drugs are said to be used "in combination".
[0229] The two agents in the combination act synergistically to produce an effect on the target cells that is greater than the effect of either drug alone. Such a benefit is manifested as a statistically significant improvement in a given parameter of target cell effect. In embodiments, the improvement produced by treatment with a drug combination may be manifested as at least additive, and desirably synergistic, compared to the results obtained when using only a single agent.
[0230] In use, the various drugs in the combination can be formulated according to the dosage size and form and regimen of the monotherapy. In this regard, as revealed in appropriately controlled clinical trials, the synergistic effect of their combined use can allow the use of slightly reduced dosage size or frequency.
[0231] According to one embodiment, the P-selectin inhibitor and the immunomodulator are administered simultaneously.
[0232] According to another embodiment, the P-selectin inhibitor and the immunomodulator are administered sequentially, wherein the first agent is administered, for example, 30 minutes, 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, one week, one month, or longer after the second agent. One skilled in the art is well able to make such a determination. In another embodiment, the P-selectin inhibitor and the immunomodulator are administered sequentially, wherein the second agent is administered, for example, 30 minutes, 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, one week, one month, or longer after the first agent.
[0233] The P-selectin inhibitors (and immunomodulators) of some embodiments of the present invention may be administered to an organism alone or in the form of a pharmaceutical composition, wherein the pharmaceutical composition is mixed with a suitable carrier or excipient.
[0234] As used herein, "pharmaceutical composition" refers to a preparation of one or more active ingredients described herein with other chemical components, such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
[0235] The term "active ingredient" herein refers to the P-selectin inhibitor responsible for the biological effect.
[0236] Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutically acceptable carrier" are used interchangeably to refer to a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. Such phrases include adjuvants.
[0237] The term "excipient" herein refers to an inert substance added to a pharmaceutical composition to further facilitate administration of the active ingredient. Examples of excipients, but not limited to, include calcium carbonate, calcium phosphate, various sugars and starch types, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
[0238] Techniques for formulation and administration of drugs may be found in "Remington's Pharmaceutical Sciences", Mack Publishing Company, Easton, Pa., latest edition, which is incorporated herein by reference.
[0239] Suitable routes of administration may include, for example, oral, rectal, transmucosal, particularly nasal, enteral or parenteral administration, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, directly intraventricular, intracardiac, for example, into the right or left ventricular cavity, into the common coronary artery cavity, intravenous, intraperitoneal, intranasal, or intraocular injections.
[0240] Conventional approaches to drug delivery to the central nervous system (CNS) include: neurosurgical strategies (e.g., intracerebral injection or intraventricular infusion); molecular manipulation of agents (e.g., production of chimeric fusion proteins containing transport peptides with affinity for endothelial cell surface molecules, conjugated to agents that cannot cross the BBB by themselves), attempting to exploit one of the endogenous transport pathways of the BBB; pharmacological strategies aimed at increasing the lipid solubility of agents (e.g., conjugating water-soluble agents to lipid or cholesterol carriers); and temporary disruption of the integrity of the BBB due to hyperosmotic disruption (infusion of mannitol solutions into the carotid artery or use of bioactive agents such as angiotensin peptides). However, each of these strategies has limitations, such as inherent risks associated with invasive surgical procedures, size limitations due to inherent limitations of endogenous transport systems, possible adverse biological side effects of systemic administration of chimeric molecules containing carrier motifs, possible activation of the chimeric molecules outside the central nervous system, and the risk of brain damage in brain regions where the BBB is disrupted, making them suboptimal delivery methods.
[0241] Alternatively, the pharmaceutical composition may be administered locally rather than systemically, such as by injecting the pharmaceutical composition directly into the patient's brain.
[0242] The pharmaceutical compositions of some embodiments of the present invention can be manufactured by methods well known in the art, for example, by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, embedding or lyophilizing methods.
[0243] Therefore, the pharmaceutical compositions used according to some embodiments of the present invention can be formulated in a conventional manner using one or more physiologically acceptable carriers including excipients and adjuvants, which facilitate processing of the active ingredients into pharmaceutically acceptable preparations. The appropriate formulation depends on the chosen route of administration.
[0244] For injection, the active ingredients of the pharmaceutical composition can be formulated into aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
[0245] For oral administration, pharmaceutical compositions can be easily formulated by combining the active compound with a pharmaceutically acceptable carrier well known in the art. Such carriers enable pharmaceutical compositions to be formulated into tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, etc., for oral administration by patients. Solid excipients can be used to prepare pharmacological preparations for oral administration, optionally grinding the resulting mixture, and processing the granular mixture after adding suitable adjuvants (if necessary) to obtain tablets or dragee cores. Suitable excipients, in particular fillers, such as sugars, including lactose, sucrose, mannitol or sorbitol; cellulose preparations, such as corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose; and / or physiologically acceptable polymers, such as polyvinylpyrrolidone (PVP). If necessary, disintegrants such as cross-linked polyvinyl pyrrolidone, agar or alginic acid or a salt thereof, such as sodium alginate, can be added.
[0246] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyes or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
[0247] Pharmaceutical compositions that can be taken orally include push-fit capsules made of gelatin and soft sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Push-fit capsules may contain the active ingredient, mixed with a filler such as lactose, a binder such as starch, a lubricant such as talc or magnesium stearate, and an optional stabilizer. In soft capsules, the active ingredient may be dissolved or suspended in a suitable liquid, such as a fatty oil, liquid paraffin, or liquid polyethylene glycol. In addition, stabilizers may be added. All oral formulations should be in dosages suitable for the selected route of administration.
[0248] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
[0249] For administration by nasal inhalation, the active ingredient used according to some embodiments of the present invention can be conveniently delivered in the form of an aerosol spray from a pressurized pack or nebulizer, using a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve for delivering a metered amount. Capsules and cartridges for a dispenser can be formulated, for example gelatin, containing a powder mix of the compound and a suitable powder base such as lactose or starch.
[0250] The pharmaceutical compositions described herein can be formulated for parenteral administration, for example, by bolus injection or continuous infusion. The formulations for injection can be in unit dosage form, for example, in ampoules or in multi-dose containers, optionally with the addition of preservatives. The compositions can be suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain preparatants, such as suspending agents, stabilizers and / or dispersants.
[0251] Pharmaceutical compositions for parenteral administration include aqueous solutions of active agents in water-soluble form. In addition, suspensions of active ingredients can be prepared into suitable oily or water-based injection suspensions. Suitable lipophilic solvents or carriers include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may include substances that can increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol or dextran. Optionally, the suspension may also include suitable stabilizers or agents that increase the solubility of the active ingredient to prepare high concentration solutions.
[0252] Alternatively, the active ingredient may be in powder form for mixing with a suitable vehicle, eg, a sterile, pyrogen-free water based solution, before use.
[0253] Pharmaceutical compositions of some embodiments of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, eg, conventional suppository bases such as cocoa butter or other glycerides.
[0254] Pharmaceutical compositions suitable for use in some embodiments of the present invention include compositions in which the active ingredient is present in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount refers to an amount of the active ingredient (P-selectin inhibitor) that is effective to prevent, alleviate or improve the symptoms of a disease (e.g., a P-selectin inhibitor) or to prolong the survival of a subject receiving treatment.
[0255] Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
[0256] For any formulation used in the methods of the present invention, a therapeutically effective amount or dosage can be initially estimated from in vitro and cell culture assays. For example, a dosage can be formulated in an animal model to achieve a desired concentration or titer. Such information can be used to more accurately determine an effective dosage in humans.
[0257] The toxicity and therapeutic effects of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, cell culture or experimental animals. The data obtained from such in vitro and cell culture analyses and animal studies can be used to formulate dosage ranges for humans. The dosage may vary depending on the dosage form used and the route of administration used. The exact formulation, route of administration and dosage can be selected by individual physicians based on the patient's condition. (See, for example, Finger et al., 1975, "The Pharmacological Basis of Therapeutics", Chapter 1, page 1).
[0258] Dosage and interval can be adjusted individually to provide levels of the active ingredient (e.g., brain levels) that are sufficient to induce or inhibit a biological effect (minimal effective concentration, MEC). The MEC will vary for each preparation but can be estimated based on in vitro data. Doses necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to measure plasma concentrations.
[0259] Any formulation, dosage or therapeutically effective amount used in the method of the present invention can be preliminarily estimated from in vitro and cell culture analysis. For example, a dosage can be formulated in an animal model to achieve a desired concentration or titer. Such information can be used to more accurately determine useful dosages for humans. Since it is expected that the administration of the disclosed combination produces better results than the administration of a single agent, the therapeutically effective dose of the various agents in the combination therapy may be, for example, less than 50%, 40%, 30%, 20% or even less than 10% of the FDA approved dosage.
[0260] For example, the therapeutically effective dose of an immunomodulator (e.g., an immunomodulatory antibody) in a combination therapy may be, for example, less than 50%, 40%, 30%, 20%, or even less than 10% of the FDA-approved dose. Conversely, the therapeutically effective dose of a P-selectin inhibitor in a combination therapy may be, for example, less than 50%, 40%, 30%, 20%, or even less than 10% of the FDA-approved dose.
[0261] Depending on the severity and responsiveness of the condition to be treated, administration may be single or multiple administrations, with the course of treatment lasting from several days to several weeks, or until the disease state is cured or diminished.
[0262] According to another aspect of the present invention, a method for treating glioblastoma or brain metastatic melanoma in a subject in need thereof is provided, comprising administering a therapeutically effective amount of rizumab and an anti-PD1 antibody to the subject, thereby treating glioblastoma or brain metastatic melanoma.
[0263] As used herein, the term "glioblastoma" (GBM), also known as glioblastoma multiforme or "grade IV astrocytoma" according to the WHO classification, refers to a primary tumor of the central nervous system derived from glial cells. GBM is one of the most deadly human cancers, with an annual incidence of about 3.5 / 100,000 worldwide (Krafsey, TF, WK Caveney and PS Michel, Glioblastoma: From Molecular Pathology to Targeted Therapy, Annu Rev Pathol, 2014, 9: Pages 1-25). Despite the current active treatment standards including surgery, chemotherapy and radiotherapy, however, the prognosis is still very poor, with an overall survival of about 15 months.
[0264] According to a specific embodiment, the glioblastoma is in an early stage (eg, when the tumor is less than 14 mm in diameter).
[0265] Exemplary therapeutic regimens for treating cancer (e.g., glioblastoma) are as follows:
[0266] 1. Treating the subject with rizumab (e.g., 1-20 mg / kg, more specifically about 5 mg / kg) + anti-PD1 antibody (e.g., nivolumab) (e.g., 1-20 mg / kg, more specifically about 3 mg / kg) once every two weeks;
[0267] 2. After two or three rounds of (1), treat the subject with rizumab (e.g., 1-20 mg / kg, more specifically about 5 mg / kg) once every four weeks. In Phase 2, an anti-PD1 antibody (e.g., nivolumab) (1-20 mg / kg, more specifically about 3 mg / kg) may be administered once every two weeks or once every four weeks.
[0268] According to a specific embodiment, the active agent is administered following resection of a glioblastoma tumor.
[0269] The amount of composition to be administered will, of course, depend on the subject to be treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, and the like.
[0270] If desired, the compositions of some embodiments of the present invention may be presented in the form of a package or dispenser device, such as a kit approved by the FDA, which may include one or more unit dosage forms containing active ingredients. For example, the package may include metal or plastic foil, such as a blister package. The package or dispenser device may be accompanied by instructions for administration. The package or dispenser may also be provided with a notice associated with the container, the form of which is specified by a government agency that manages the manufacture, use or sale of drugs, and the notice reflects the agency's approval of the form of the composition or human or veterinary administration. For example, such a notice may be a prescription drug label approved by the U.S. Food and Drug Administration or an approved product instruction sheet. Compositions comprising the preparations of the present invention may also be prepared, the preparations being formulated in a compatible pharmaceutical carrier, placed in an appropriate container, and labeled to treat the indicated condition, as further described above.
[0271] Treatment methods:
[0272] The term "treat" refers to inhibiting, preventing or arresting the development of a pathology (disease, disorder or condition) and / or causing a reduction, alleviation or regression of a pathology. Those skilled in the art will appreciate that various methods and assays can be used to assess the development of a pathology, and similarly, various methods and assays can be used to assess the reduction, alleviation or regression of a pathology.
[0273] As used herein, the term "preventing" refers to keeping a disease, disorder or condition from occurring in a subject who may be at risk for the disease, but has not yet been diagnosed as having the disease.
[0274] Treatment options:
[0275] As used herein, the phrase "treatment regimen" refers to a treatment plan that specifies the type of treatment, dosage, schedule, and / or duration of treatment provided to a subject in need (e.g., a subject diagnosed with a pathology). The selected treatment regimen may be an active treatment regimen that is expected to produce the best clinical outcome (e.g., complete cure of the pathology), or may be a milder treatment regimen that relieves the symptoms of the pathology but results in an incomplete cure of the pathology. It should be understood that in some cases, a more active treatment regimen may be associated with some discomfort or adverse side effects (e.g., damage to healthy cells or tissues) of the subject. Treatment types may include surgery (e.g., removal of lesions, diseased cells, tissues, or organs), cell replacement therapy, therapeutic drugs (e.g., receptor agonists, antagonists, hormones, chemotherapeutic agents) administered in a local or systemic manner, radiation therapy using an external source (e.g., an external beam) and / or an internal source (e.g., brachytherapy), and / or any combination thereof. The dosage, schedule, and duration of treatment may vary depending on the severity of the pathology and the type of treatment selected, and those skilled in the art are able to adjust the type of treatment, dosage, treatment schedule, and duration of treatment.
[0276] As used herein, the term "about" refers to ± 10%.
[0277] The terms "comprises," "comprising," "includes," "including," "having" and their cognates mean "including but not limited to."
[0278] The term "consisting of" means "including but limited to".
[0279] The term "consisting essentially of" means that the composition, method or structure may include additional ingredients, steps and / or parts, but only if the additional ingredients, steps and / or parts do not materially change the basic and novel characteristics of the claimed composition, method or structure.
[0280] As used herein, the singular forms "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.
[0281] Throughout this application, various embodiments of the present invention can be presented in range form. It should be understood that the description in range form is only for convenience and brevity and should not be interpreted as a strict limitation of the scope of the present invention. Therefore, the description of the range should be deemed to clearly disclose all possible sub-ranges and single numerical values within this range. For example, the description of a range such as from 1 to 6 should be deemed to clearly disclose sub-ranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc.), and individual numbers within this range, such as 1, 2, 3, 4, 5 and 6. Regardless of the width of the range, this applies.
[0282] Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integer) within the indicated range. The phrases "ranging / ranges between" a first indicated numeral and a second indicated numeral and "ranging / ranges from" a first indicated numeral to" a second indicated numeral are used interchangeably herein and are meant to include the first indicated numeral and the second indicated numeral, and all fractions and integers therebetween.
[0283] The term "method" as used herein refers to ways, means, techniques and procedures for accomplishing a given task, including, but not limited to, ways, means, techniques and procedures known to practitioners in the fields of chemistry, pharmacology, biology, biochemistry and medicine or readily developable from known ways, means, techniques and procedures.
[0284] As used herein, the term "treating" includes abrogating, substantially inhibiting, slowing or reversing the progression of a disease, substantially ameliorating the clinical or aesthetic symptoms of a disease, or substantially preventing the appearance of clinical or aesthetic symptoms of a disease.
[0285] It should be understood that certain features of the invention described in the context of separate embodiments for the sake of clarity may also be provided in combination in a single embodiment. Conversely, various features of the invention described in the context of a single embodiment for the sake of brevity may also be provided separately or in any suitable subcombination or in any suitable manner in any other described embodiment of the invention. Certain features described in the context of various embodiments should not be considered essential features of such embodiments unless the embodiment does not function without those elements.
[0286] Various embodiments and aspects of the present invention as delineated hereinabove and claimed in the claims section below find experimental support in the following examples.
[0287] Examples
[0288] Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non-limiting fashion.
[0289] Material
[0290] DMEM, fetal bovine serum (FBS), L-glutamine, penicillin, streptomycin, mycoplasma detection kit, EZ-RNA II total RNA isolation kit and fibronectin (1 mg / ml, dilution: 1:100) were purchased from Bio-Industry Ltd. (Beit HaEmek Kibbutz, Israel). Percoll medium (Cat. No. p4937) and all other chemical reagents including salts and solvents were purchased from Sigma-Aldrich (Rehovot, Israel). Milli-Q water was prepared using a Millipore water purification system. Amicon Ultra centrifugal filters; molecular weight cut-off (MWCO) 5 or 3 kDa and Poly-L-Lysine (PLL) (Cat. No. A-005-C; 0.1 mg / ml) were purchased from Merck Millipore (Burlington, MA, USA). The qScriptTM cDNA synthesis kit was purchased from Quantabio (Beverly, MA, USA). Fast SYBRTM green Master Mix was purchased from Applied Biosystems (CA, USA). Collagenase IV, Dispase II (neutral protease) and DNase I were purchased from Worthington Biochemical Corporation (NJ, USA). RBC lysate (Cat. No. 420301) was purchased from BioLegend (San Diego, CA, USA). MACS MS magnetic columns for cell separation (Cat. No. 130-042-201), CD11b microbeads for cell separation (Cat. No. 130-093-634) and CD45 (TIL) microbeads for cell separation (Cat. No. 130-110-618) were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). SELP inhibitor (SELPi) KF38789 (Cat. No. 2748) was purchased from Tocris BioScience (Bristol, UK).Recombinant human SELP (Cat. No. ADP3; Lot. ARL6019071), recombinant mouse SELP (rSELP) (Cat. No. 10094-PS; Lot. DKLJ0118111), human SELP ELISA kit (Cat. No. DPSE00), total NO / nitrite / nitrate immunoassay (Cat. No. KGE001), mouse XL cytokine array kit (Cat. No. ARY028), human cytokine array kit (Cat. No. ARY005B), anti-human PSGL-1 neutralizing antibody (Cat. No. MAB3345; Lot. CLYK0120111; Clone No. 688102), and anti-human SELP neutralizing antibody (Cat. No. AF137; Lot. FBX0518051) were purchased from R&D Systems (Minneapolis, MN, USA). Human L-507 cytokine array kit (Cat. No. AAH-BLM-1A-4, Lot No. 102920 009) was purchased from RayBiotech (Norcross, GA, USA). Anti-human / mouse CD44 neutralizing antibody (Cat. No. NBP2-2530; Lot No. VC289186) was purchased from Novus (CO, USA). Anti-mouse PSGL-1 neutralizing antibody (Cat. No. BE0188; Lot No. 676818M2) was purchased from Bio X Cell (MA, USA). MEBCYTO apoptosis kit was purchased from MBL International (UK), and recombinant mouse GM-CSF (Cat. No. 315-03-50 ug; Lot No. 091855) was purchased from PeproTech (Rehovot, TN). Latex beads for phagocytosis assay (Cat. No. L4655) were purchased from Sigma-Aldrich (Rehovot, TN, Israel). Gold conjugated DAPI (Cat. No. p36935) and Hoechst 33342 (Cat. No. H3570) were purchased from Invitrogen (Carlsbad, CA, USA). Mayer's hematoxylin solution (Cat. No. 05-06002) and eosin Y solution (Cat. No. 05-10002) were purchased from Bio-Optica (Milan, Italy). Anti-PD-1 antibody was purchased from ichorbio Ltd. (Wantage, USA, Cat. No. ICH1132; Lot. No. 1220L520). Immunostaining antibody: mouse anti-human SELP (Cat. No. BBA1; Lot. No. APB081704; clone BBIG-E; dilution 1:30) was purchased from R&D Systems (Minneapolis, MN, USA). Mouse anti-mouse SELP (Cat. No. 148302; Lot No. B186735; clone RMP-1; dilution 1:50) was purchased from BioLegend (San Diego, CA, USA). Goat anti-mouse Alexa 647 (Cat. No. ab15115; Lot. No. GR309891-3; dilution 1:300). Flow cytometry antibodies: mouse anti-human SELP (Cat. No. BBA1; Lot. No. APB081704; clone: BBIG-E; dilution 1:20) and mouse IgG1 isotype control (Cat. No. mab002; dilution 1:20) were purchased from R&D Systems (Minneapolis, MN, USA).
[0291] method
[0292] Cell culture:
[0293] Metastatic melanoma 131 / 4-5B1 cells
[92] were cultured in RPMI medium supplemented with 10% FBS, 100 IU / mL penicillin, 100 μg / mL streptomycin, 12.5 IU / mL nystatin, and 2 mM L-glutamine. Primary melanoma A375 cells (ATCC, USA) were cultured in RPMI medium supplemented with 10% FBS, 100 IU / mL penicillin, 100 μg / mL streptomycin, 12.5 IU / mL nystatin, 2 mM L-glutamine, 1 mM sodium pyruvate, and 25 mM HEPES. Primary melanoma WM115 cells (ECACC, Porton Down, Salisbury, UK) were cultured in MEM medium supplemented with 10% FBS, 100 IU / mL penicillin, 100 μg / mL streptomycin, 12.5 IU / mL nystatin and 2 mM L-glutamine, 1 mM sodium pyruvate and 1x MEM NAA. Primary melanoma B16-F10 cells (ATCC, USA) were cultured in DMEM medium supplemented with 10% FBS, 100 U / mL penicillin, 100 μg / mL streptomycin, 12.5 IU / mL nystatin and 2 mM L-glutamine. Primary melanoma B2905 was grown in RPMI supplemented with 10% FBS, 100 U / mL penicillin, 100 μg / mL streptomycin, 12.5 IU / mL nystatin, 25 mM HEPES, and 2 mM L-glutamine. Primary melanoma Mel-ret cells (kindly provided by Neta Erez) were grown in RPMI supplemented with 10% FBS, 100 U / mL penicillin, 100 μg / mL streptomycin, 12.5 IU / mL nystatin, 1 mM sodium pyruvate, and 2 mM L-glutamine. Primary melanoma D4M.3A cells (kindly provided by David W. Mullis) were grown in Advanced DMEM supplemented with 5% FBS, 100 IU / mL penicillin, 100 μg / mL streptomycin, 12.5 IU / mL nystatin, and 2 mM Glutamax. All melanoma cell lines were labeled using pQC-mCherry retroviral particles as described previously.
[0294] Isolation of primary mouse microglia:
[0295] Brains removed from healthy 5-week-old 57BL / 6 mice were minced and cultured for 50 minutes at 37°C with 1mg / ml collagenase IV, 2mg / ml Dispase II (neutral protease) and 0.02U / ml DNase I. RBC lysis buffer was used to lyse red blood cells (RBC), and then myelin was separated using a Percoll gradient. The resulting cell suspension was then cultured with CD11b microbeads and the desired cell population was separated on a MACS MS magnetic column. Mouse microglia were then inoculated onto poly-L-lysine (PLL) coated plates in microglial culture medium (ScienCell, California, USA).
[0296] Splenocyte isolation:
[0297] Splenocytes were freshly isolated from the spleens of healthy 7- to 11-week-old C57BL / 6 mice. The spleens were mashed and passed through a 0 μm nylon filter before RCB lysis. Flasks were coated with anti-CD3ε (Cat. No. 100340; Batch No. B302116; Clone No. 145-2C11) antibodies, and splenocytes (30x106 cells / 75cm2 flask) were cultured with 2 μg / ml anti-CD28 (Cat. No. 102116; Batch No. B331922; Clone No. 3751) and 10 U / ml rhIL-2 for 6 days.
[0298] Flow cytometry:
[0299] For flow cytometry analysis, cells were harvested using a cell scraper and then washed with PBS, followed by additional washes in PBS supplemented with 1% BSA and 5 mM EDTA (FACS buffer). Tumor spheroids were recovered from Matrigel using cell recovery solution (Corning) and washed with FACS buffer. To assess the expression of P-selectin, cells were incubated with anti-human or anti-mouse P-selectin antibodies on ice for 1 hour, followed by washing and incubation with anti-mouse IgG binding protein labeled with Alexa-488 on ice for 1 hour.
[0300] Co-culture proliferation assay:
[0301] Primary mouse microglia were seeded in 24-well plates (Corning) at different concentrations, and the same amount of mouse Mel-ret labeled with mCherry was added 24 to 72 hours after seeding (ratios of 1:4, 1.5:1, 3:1, 6:1). The culture plates were then cultured in microglia culture medium for 96 hours (37°C; 5% CO2), and the proliferation of fluorescently labeled cells was measured by the IncuCyte Zoom live cell analysis system (Essen Bioscience). Melanoma cells in microglia culture medium were used as controls.
[0302] Co-culture of splenocytes and melanoma spheroids:
[0303] Tumor spheroids were prepared by D4M m-cherry labeling. D4M spheroids were prepared by seeding 500 cells in each well of a U-bottom, low-attachment 96-well plate. Splenocytes were harvested from C57BL / 6J mice and seeded in a 96-well plate containing D4M spheroids at a ratio of 1:50 and cultured with complete RPMI supplemented with 10% (v / v) FBS, 1% (v / v) PEST, 1% (v / v) HEPES, 1% (v / v) sodium pyruvate, and 0.1% (v / v) 2-mercaptoethanol. Co-cultured cells were treated with SELP inhibitors KF38789 (Tocris, 0.5 μM) or PSI-697 (10 μM) with or without anti-PD-1 antibodies (0.5 mg / ml). The growth of fluorescently labeled melanoma spheroids was detected using the IncuCyte Zoom live cell analysis system (Essen Bioscience).
[0304] RNA Isolation:
[0305] Total RNA was isolated using the EZ-RNA II Total RNA Isolation Kit (Bio-Industry Ltd., Israel) according to the manufacturer's protocol. Briefly, samples were lysed using 0.5 ml of denaturing solution / 10 cm2 culture dish. Water-saturated phenol was then added and the samples were centrifuged. Isopropanol was added to precipitate RNA, and the centrifuged RNA pellet was washed with 75% ethanol, centrifuged, and resuspended with ultrapure double distilled water. The total RNA was isolated using the EZ-RNA II Total RNA Isolation Kit (Bio-Industry Ltd., Israel) according to the manufacturer's V3.5 user manual (Nano-Drop Technologies, Wilmington, Delaware). RNA concentration was assessed using an ND-1000 spectrophotometer.
[0306] cDNA Synthesis:
[0307] RT-PCR was performed using the qScriptTM cDNA synthesis kit to synthesize cDNA according to the manufacturer's protocol. Briefly, 1 μg of total RNA sample was mixed with qScript reverse transcriptase, dNTPs, and nuclease-free water. The reaction tube was then incubated at 42°C for 30 minutes and heated at 85°C for 5 minutes to stop cDNA synthesis.
[0308] Real-time PCR:
[0309] The expression levels of target genes were assessed by SYBR green real-time PCR (StepOne plus, Life Technologies) and normalized to the GAPDH housekeeping gene.
[0310] Animals and Ethics Statement:
[0311] Animals were housed in the Tel Aviv University Animal Facility. All experiments were ethically approved by the Institutional Animal Care and Use Committee (IACUC) of Tel Aviv University (protocol numbers: 01-16-054 and 01-21-006) and performed in accordance with NIH guidelines.
[0312] Animal Model:
[0313] To generate primary melanoma tumors, mouse or human cells (0.5x10 6 cells / 100 μl) were inoculated intradermally (id) into immunocompetent C57BL / 6 mice or 6- to 8-week-old male immunocompromised SCID mice. To generate intracranial melanoma tumors, mouse or human cells (1.5 x 10 4 Cells / 2 μl) were stereotaxically inoculated intracranially into the striatum of 8- to 10-week-old immunocompetent C57BL / 6 mice or 6- to 8-week-old male immunocompromised SCID mice. Mouse weight changes were monitored twice a week, and tumor growth was detected using 4.7T MRI (MR Solutions, UK). Mice were euthanized and brains were harvested for further immunostaining and flow cytometry analysis.
[0314] Cryo-OCT tissue fixation:
[0315] Tumor-bearing mice were anesthetized with intraperitoneal injection of ketamine (150 mg / kg) and xylazine (12 mg / kg) and perfused with PBS followed by 4% paraformaldehyde (PFA). The brains were harvested and incubated with 4% PFA for 4 hours, followed by 0.5 M sucrose (BioLab) for 1 hour, followed by 1 M sucrose overnight (overnight, ON). The brains were then embedded in optimal cutting temperature (OCT) compound (Scigen) on dry ice and stored at -80°C.
[0316] Immunostaining:
[0317] OCT-embedded tumor samples were cut into 5 μm thick sections. Staining was performed using a BOND RX automated stainer (Leica). Sections were stained with hematoxylin and eosin (H&E) and immunostained for P-selectin. Prior to antibody incubation, slides were incubated with 10% goat serum in PBS x1 + 0.02% Tween-20 for 30 minutes to block nonspecific binding sites. Slides were incubated with primary antibodies for 1 hour, followed by washing and incubation with secondary antibodies for another hour. They were then washed and immunostained with DAPI. Gold mounting was performed and then covered with a coverslip. The stained samples were imaged using the EVOS FLAuto cell imaging system (ThermoFisher Scientific). ImageJ1.52v software was used to image and quantify at least three fields of view for each individual sample. The total area of staining in each image was detected after background subtraction using a single-color image representing the relevant marker to quantify positive staining.
[0318] Statistical analysis:
[0319] Data are expressed as mean ± standard deviation (SD) for in vitro analysis or mean ± standard error (SEM) for in vivo analysis. When comparing two groups, unpaired, two-sided t-test was used to determine statistical significance, and when comparing more than two groups, multiple comparison ANOVA tests were used to determine statistical significance. P < 0.05 was considered statistically significant. For Kaplan-Meier survival curves, the log rank test was used to determine the p value. For in vivo tumor growth curves, one-way analysis of variance, Dunn's test or Holm-Sidak test was used to determine the p value. GraphPad Prism 8 was used for statistical analysis.
[0320] result
[0321] GB tumors are characterized by a highly suppressive tumor microenvironment. To investigate whether PD-1 and its ligand PD-L1 are highly expressed in GB tumors, the GB patient database was explored using the GlioVis data portal (Bowman, RL et al., Neuro-oncology, 2017, 19(1), 139-141). The analysis showed that both PD-1 (PDCD1) and PD-L1 (CD274) were highly expressed in GB samples compared to healthy brain and low-grade glioma samples. In addition, the study found that their expression was negatively correlated with patient survival ( Figure 1A to Figure 1B ), indicating the role of the PD-1 / PDL-1 axis in GB progression. It was further found that PSGL-1 (SELPLG) expression was positively correlated with the expression of both PD-1 and PDL-1, and SELP expression was positively correlated with PD-L1 expression in GB patient tissues. It may indicate that immunosuppressive microglia / macrophages express both PSGL-1 and PD-L1 and promote T cells to express PD-1, while GB cells express SELP and PD-L1. These results may explain the lack of therapeutic benefit of anti-PD-1 as a monotherapy for GB patients.
[0322] To evaluate whether the SELP and PD-1 axis is associated with other brain tumors, FFPE samples of normal human brain and patient samples of melanoma, breast, lung, and CRC brain metastasis (BM), as well as patient samples of diffuse intrinsic pontine glioma (DIPG) were collected. Immunostaining showed that SELP and PD-L1 were highly expressed in all samples, PSGL-1 was highly expressed in melanoma, breast and lung DIPG and BM, and PD-1 was highly expressed in melanoma and lung BM ( FIG. 2A to FIG. 2B ). In addition, we found that SELP was highly expressed in samples from patients with primary melanoma, breast cancer, lung cancer, and pancreatic ductal adenocarcinoma (PDAC). PSGL-1 was found to be highly expressed in samples from primary melanoma, breast cancer, and lung cancer, and PD-1 and PD-L1 were also highly expressed in samples from primary melanoma, PDAC, and lung cancer ( FIG. 3A to FIG. 3B ).
[0323] To investigate the role of microglia in brain metastasis of cancer, several mouse models of melanoma brain metastasis (MBM) were established. Using Iba-1 immunostaining, activated microglia were found in tumor sites of all different models and formalin-fixed paraffin-embedded (FFPE) samples of MBM patients. Figure 4A To evaluate the impact of microglia on MBM progression, primary mouse microglia were co-cultured with the mouse RET MBM cell line and cancer cell proliferation was observed. There was a direct correlation between the increased proliferation rate of mouse RET MBM cells and the concentration of mouse microglia in the culture ( Figure 4B ).
[0324] In addition, human WM115 and mouse D4M.3A melanoma cell lines were used to establish a 3D in vitro model of melanoma. When microglia were present in the spheroids, an increase in the invasiveness of the D4M.3A spheroids was observed ( Figure 4C ), and higher expression of SELP in melanoma cells grown in 2D plastic culture dishes compared to those in melanoma cells grown in 2D plastic culture dishes ( FIG. 5A to FIG. 5C ). This expression increased over time after seeding Matrigel on D4M.3A spheroids ( Figure 5C ).
[0325] To evaluate the therapeutic potential of SELP inhibitor (SELPi) and anti-PD-1 antibody combination therapy, D4M.3A tumor spheroids were co-cultured with primary mouse microglia. After spheroid formation, freshly isolated mouse splenocytes were added together with different treatments, and the killing effect of splenocytes on cancer cells was monitored. The results showed that in spheroids composed of both melanoma cells and microglia, SELPi and anti-PD-1 antibody treatment had a synergistic effect, while only a slight effect was observed in D4M.3A spheroids without microglia ( FIG. 6A to FIG. 6B ). This suggests that microglia are required to induce splenocytes to kill cancer cells following SELP and PD-1 inhibition.
[0326] After validating these results in other cancer models, we found that SELP is highly expressed in the EMT-6 mouse breast cancer cell line ( Fig. 7A Furthermore, using human astrocyte-MDA-MB-231 breast cancer multicellular 3D spheroids, we managed to reduce cancer cell invasion after SELP inhibition ( Figure 7B ). This suggests that SELP is also important for the interaction between breast cancer cells and astrocytes.
[0327] When looking at lung cancer cells, it was observed that the invasiveness of human A549 spheroids increased when co-cultured with human microglia ( Fig. 8A Flow cytometric analysis of these spheroids showed that SELP and PSGL-1 were highly expressed in A549 cells and human microglia, respectively ( Figure 8B Indeed, SELP inhibition reduced spheroid growth and invasion in the A549-microglia 3D model ( Figure 8C -D).
[0328] In conclusion, the results suggest that combining SELP inhibition with other immunomodulatory agents, such as anti-PD-1, has potential therapeutic benefits for both primary and secondary brain malignancies.
[0329] Although the present invention has been described in conjunction with its specific embodiments, it is apparent that many alternatives, modifications and variations are apparent to those skilled in the art. Therefore, it is intended to cover all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
[0330] It is the intention of the applicant that all publications, patents and patent applications mentioned in this specification should be incorporated by reference in their entirety into this specification, just as each individual publication, patent or patent application is clearly and individually indicated to be incorporated by reference herein when cited. In addition, the citation or identification of any reference in this application should not be construed as an admission that such reference can serve as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting. In addition, any priority document of this application is hereby incorporated by reference in its entirety herein.
Claims
1. A method for treating brain metastatic cancer in a subject in need thereof, characterized in that: The method comprises administering to the subject a therapeutically effective amount of an agent that specifically reduces the amount and / or activity of P-selectin and an immunomodulatory agent, thereby treating the brain metastatic cancer.
2. A method for treating pancreatic cancer or renal cancer in a subject in need thereof, characterized in that: The method comprises administering to the subject a therapeutically effective amount of an agent that specifically reduces the amount and / or activity of P-selectin, thereby treating the pancreatic cancer or renal cancer.
3. A method of treating cancer in a subject in need thereof, wherein the cancer is selected from the group consisting of pancreatic cancer, lung cancer, breast cancer, primary melanoma and renal cancer, characterized in that: The method comprises administering to the subject a therapeutically effective amount of an agent that specifically reduces the amount and / or activity of P-selectin and an immunomodulatory agent, thereby treating the cancer.
4. The method according to claim 1, characterized in that: The brain metastatic cancer is brain metastatic melanoma, brain metastatic breast cancer, brain metastatic lung cancer, or brain metastatic colorectal cancer.
5. The method according to any one of claims 1, 2 or 3, characterized in that: The agent that specifically reduces the amount and / or activity of P-selectin specifically binds to P-selectin or a polynucleotide encoding the P-selectin.
6. The method according to claim 1, 2 or 3, characterized in that: The agent that specifically reduces the amount and / or activity of P-selectin binds to P-selectin glycoprotein ligand-1 (PSGL-1) or a polynucleotide encoding the PSGL-1.
7. The method according to claim 2, characterized in that: The method further comprises administering to the subject an immunomodulatory agent.
8. The method according to any one of claims 1, 3 or 7, characterized in that: The immunomodulator includes an immunomodulatory antibody.
9. The method according to claim 8, characterized in that: The immunomodulatory antibody is selected from the group consisting of anti-CTLA4, anti-CD40, anti-41BB, anti-OX40, anti-PD1, anti-PDL1, anti-LAG3, anti-IDO, and anti-TIGIT.
10. The method according to any one of claims 1 to 9, characterized in that: The agent that specifically reduces the amount and / or activity of P-selectin is an inhibitory antibody that binds to and inhibits P-selectin.
11. The method according to claim 10, characterized in that: The inhibitory antibody is rizenlizumab or inclekumab.
12. The method according to claim 11, characterized in that: The dose of rizumab is about 5 mg / kg once every two weeks or 5 mg / kg once every four weeks.
13. The method according to claim 10, characterized in that: The inhibitory antibody is linked to a therapeutic agent.
14. The method according to claim 10, characterized in that: The inhibitory antibody is not linked to a therapeutic agent.
15. The method according to any one of claims 1 to 9, characterized in that: The agent that specifically reduces the amount and / or activity of P-selectin is a small molecule agent.
16. The method according to any one of claims 1 to 9, characterized in that: The agent that specifically reduces the amount and / or activity of P-selectin is a polynucleotide agent.
17. The method according to any one of claims 7 to 16, characterized in that: The agent that specifically reduces the amount and / or activity of P-selectin is co-formulated with the immunomodulator.
18. The method according to any one of claims 1 to 17, characterized in that: The agent that specifically reduces the amount and / or activity of P-selectin is contained in a nanoparticle.
19. The method of claim 18, wherein: The nanoparticles are linked to a targeting moiety to enhance transport across the blood-brain barrier.
20. The method according to any one of claims 1 to 17, characterized in that: The agent that specifically reduces the amount and / or activity of P-selectin is linked to a targeting moiety to enhance delivery across the blood-brain barrier.
21. A method of treating glioblastoma in a subject in need thereof, characterized in that: The method comprises administering to the subject a therapeutically effective amount of rizumab and an anti-PD1 antibody, thereby treating the glioblastoma or brain metastatic melanoma.
22. The method of claim 21, wherein: The rizumab is administered at a dose of about 5 mg / kg once every two weeks or every four weeks.
23. The method according to claim 21 or 22, characterized in that: The anti-PD1 antibody is selected from the group consisting of pembrolizumab (Keytruda), nivolumab (Baofel), cemiplizumab (Riptiuzumab) and dostalimumab (Zamperil).
24. The method according to claim 21 or 22, characterized in that: The anti-PD1 antibody is nivolumab.
25. The method according to any one of claims 21 to 24, characterized in that: The rizumab and the anti-PD1 antibody are initially administered every two weeks for at least four weeks.
26. The method of claim 25, wherein: The dose of the anti-PD1 antibody is about 3 mg / kg once every two weeks.
Citation Information
Patent Citations
Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US20030232410A1
Use of chimeric nucleases to stimulate gene targeting
US20050026157A1
Cre / lox system with lox sites having an extended spacer region
US20060014264A1
Methods of inhibiting metastasis in cancer
US20190241665A1
Compositions and methods for reducing major thrombotic events in cancer patients
US20200171064A1
